The Role of N6-methyladenosine RNA Methylation in the Regulation of Hematopoietic Stem Cells by Lee, Heather
The Role of N6-methyladenosine RNA Methylation in 
the Regulation of Hematopoietic Stem Cells 
Heather M. Lee 
Submitted in partial fulfillment of the  
requirements for the degree of  
Doctor of Philosophy  
under the Executive Committee  




Heather M. Lee 
All Rights Reserved 
ABSTRACT 
The Role of N6-methyladenosine RNA Methylation in the 
Regulation of Hematopoietic Stem Cells 
Heather M. Lee 
Hematopoietic stem cells (HSCs) give rise to all blood cells and are characterized by 
their ability for life-long self-renewal and multilineage differentiation. HSC function is regulated 
by complex cell-intrinsic and -extrinsic pathways, but these regulatory mechanisms are not 
completely understood. Recent work has demonstrated that the epitranscriptional modification 
N6-methyladenosine (m6A) has important roles in the regulation of many physiologic and 
pathologic processes in various cell types, but it was previously unknown if and how m6A may 
regulate adult HSC function. In this work, I uncover the role for m6A in HSC regulation, both cell-
intrinsically in regulating HSC differentiation and cell–extrinsically by regulating the formation the 
HSC bone marrow niche. 
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CHAPTER 1 
The Intersection of Hematopoietic Stem Cell Regulation and m6A 
Epitranscriptional Modification. 
Sections of this chapter are modified from the published article: 
Yeojin Lee*, Matthew Decker*, Heather Lee*, and Lei Ding (2017) 
Extrinsic regulation of hematopoietic stem cells in in development, homeostasis, and diseases 




Multicellular organisms evolved tissue-specific stem cells to generate, sustain, and 
repair diverse tissue and organ types. Stem cells are constantly balancing two seemingly 
opposed functions: maintaining their undifferentiated stem cell state through self-renewal 
divisions and differentiating into downstream cells of multiple lineages. Much of what is known 
about how stem cells balance these states has been learned from hematopoietic stem cells 
(HSCs). HSCs have served as a paradigm tissue stem cell, having defined the rigorous 
standards of self-renewal and multi-lineage potential that characterize all tissue stem cells. 
HSCs give rise to all blood and immune cells in the hematopoietic system throughout life. These 
hematopoietic cells include myeloid cells, lymphoid cells, erythroid cells, and megakaryocytes 
generated from a series of restricted progenitors downstream of HSCs (Weissman and Shizuru, 
2008).  
Adult HSCs reside in the bone marrow and are primarily quiescent, but can be activated 
in response to physiological needs. This is best demonstrated in their function after 
transplantation. A single HSC can reconstitute the entire hematopoietic system of a mouse after 
irradiation, demonstrating the potency of these stem cells (Osawa et al., 1996). This ability to 
regenerate the hematopoietic system makes HSC transplantation a powerful treatment for a 
number of hematologic and autoimmune diseases. Thus, better understanding HSC biology can 
lead to improvements in current therapies for these diseases, as well as offering broader 
scientific implications for general stem cell biology. 
HSC function is regulated by complex cell-intrinsic and -extrinsic pathways, but these 
regulatory mechanisms are not completely understood. Recent work has demonstrated that the 
epitranscriptional modification N6-methyladenosine (m6A) has important roles in the regulation 
of mRNA biology that can impact fundamental cellular processes. These roles for m6A have 
been demonstrated in the context of specific cell types, including several types of stem cells and 
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hematopoietic cells, raising the question of if and how m6A may regulate adult HSC function. In 
this chapter, I will summarize the current understanding of HSC-intrinsic and -extrinsic 
regulation and explore how m6A regulates fundamental biology.  
HEMATOPOIETIC STEM CELL REGULATION 
In normal hematopoiesis, HSCs balance three states: i) division and differentiation to 
create mature hematopoietic cells, ii) division and self-renewal to populate the HSC pool, iii) 
quiescence to maintain a reservoir of HSCs for future needs (Figure 1.1a). These different 
states are controlled by a complex system of HSC-intrinsic and -extrinsic pathways that when 
disrupted can lead to hematopoietic perturbation, bone marrow failure or malignancy.  
Cell-intrinsic regulation: cell fate decisions 
As a model tissue stem cell, HSCs have been extensively studied. Through genetic 
mouse models, over 150 different genes have been shown to influence HSC biology (reviewed 
in Rossi et al., 2012). These genes belong to a large array of functional categories, including 
cell cycle programs, metabolic processes and specific signaling cascades. The full scope of this 
work has been extensively reviewed elsewhere, but of particular interest are programs that 
influence HSC fate, as the largely quiescent state and choice to self-renew versus differentiate 
distinguishes HSCs from downstream progenitor cells (Rossi et al., 2012; Eaves, 2015; Laurenti 
and Gottgens, 2018). HSC fate programs are coordinated through master regulators, often 
transcription factors or epigenetic regulators. Loss of quiescence regulators, such as Pbx1, Gfi1, 
Irgm1, Prdm16, p57 and p27 result in increased HSC proliferation and loss of the HSC pool and 
reconstitution capacity, suggesting excessive cycling exhausts their functional potential (Ficara 
et al., 2008; Hock et al., 2001; Feng et al., 2008; Aguilo et al., 2011; Zou et al., 2011). Once 
cycling, HSCs must then progress through fate determination programs to self-renew or 
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differentiate. Myc is known to be required specifically for HSC differentiation, but not self-
renewal or survival (Wilson et al., 2004), while other factors like FoxO3a and Bmi1 seem to be 
specifically required for self-renewal (Miyamoto et al., 2007; Iwama et al., 2004).  
HSCs fate pathways are known to be highly regulated by epigenetic modifiers. Examples 
include Bmi1, a polycomb group gene involved in chromatin remodeling (Iwama et al., 2004), as 
well as DNA methyltransferases. DNA methyltransferase DNMT1, which is thought to maintain 
pre-existing methylation patterns, is essential for HSC survival, as loss of Dnmt1 leads to 
complete loss of HSCs by apoptosis and death from bone marrow insufficiency (Broske et al., 
2009). DNMT1 is particularly required for HSC self-renewal and lymphocyte differentiation, as 
Dnmt1 hypomorph HSCs default to myeloerythroid differentiation (Broske et al., 2009). 
Consistent with this, DNA methylome maps demonstrate that lymphocyte lineage versus 
myeloid lineage commitment requires specific DNA methylation patterns (Ji et al., 2010; Farlik et 
al., 2016). On the other hand, loss of de novo DNA methyltransferase DNMT3a from HSCs 
leads to hypomethylation of downstream HSC progeny cells and increased multipotency gene 
expression, increasing self-renewal over differentiation (Challen et al., 2012). DNA 
demethylation also influences HSC function, as loss of Tet methylcytosine dioxygenase 2 
(TET2) also promotes HSC self-renewal and myeloproliferation (Moran-Crusio et al., 2011; Li et 
al., 2011). DNA methylation patterns not only correlate with patterns of gene expression, but 
also correlate with histone modifications and chromatin accessibility, thus providing a 
mechanism to coordinate cell fate decisions in HSCs (Farlik et al., 2016). Whether there are 
additional intrinsic molecular mechanisms that may coordinate HSC fate programs in concert 
are still emerging.   
5 
Figure 1.1 Hematopoietic stem cell regulation. 
(a) The majority of adult bone marrow hematopoietic stem cells (HSCs) are quiescent, but
HSCs can be reversibly activated into the cell cycle to self-renew and replenish the HSC pool or
differentiate to downstream progenitors.
(b) The adult HSC bone marrow niche is composed of many different cellular components,
including perivascular mesenchymal stromal cells (MSCs) that express Lepr and Prx1,
endothelial cells, sympathetic nerves, and adipocytes. Mesenchymal tissue in the limb marrow
is derived from embryonic Prx1+ MSCs. HSCs are also regulated by systemic circulating factors
such as thrombopoietin (TPO), erythropoietin (EPO) and estrogen.
 6 
Cell-extrinsic regulation: the HSC niche 
 HSCs are also regulated by extrinsic signals that connect their function to physiologic 
needs. These extrinsic signals include long-range, systemically circulating cues such as 
estrogen, erythropoietin and thrombopoietin that can influence HSC proliferation, differentiation 
and maintenance, respectively (Nakada et al., 2014; Grover et al., 2014; Decker et al., 2018). 
However, much of what is known about HSC-extrinsic regulation comes from studies of their 
local microenvironment, or niche. HSCs move through niches in different organ sites several 
times throughout life to meet distinct physiological demands. Hematopoiesis begins in the yolk 
sac blood islands and aorta-gonad-mesonephros with the emergence of hematopoietic 
progenitors and pre-HSCs with limited transplantation potential (Matsubara et al., 2005). These 
pre-HSCs migrate to the fetal liver, where they mature and expand, generating an HSC pool 
with abundant self-renewal and multi-lineage potential (Morrison et al., 1995; Rebel et al., 
1996). HSCs then start to migrate to the bone marrow, the predominant site of hematopoiesis in 
adults, around E17.5 (Christensen et al., 2004). This process depends on the expression of 
bone marrow C-X-C Motif Chemokine Ligand 12 (Cxcl12, also known as stromal cell-derived 
factor 1 or Sdf-1), as mice with loss of Cxcl12 do not establish hematopoiesis in the bone 
marrow and instead have increased HSCs circulating in the peripheral blood (Nagasawa et al., 
1996; Ara et al., 2003). 
The adult bone marrow niche is the predominant site of adult hematopoiesis. It is 
composed of many different cellular components, including perivascular mesenchymal stromal 
cells (MSCs), endothelial cells, sympathetic nerves, megakaryocytes and adipocytes (reviewed 
in Lee et al., 2017) (Figure 1.1b). Although early studies suggested osteoblasts were the key 
component of the HSC niche, accumulating evidence suggests that they are not as critical as 
initially thought (Morrison and Scadden, 2014). MSCs are a key component of the niche and 
can be identified by a number of markers, including paired related homeobox 1 (Prx1), leptin 
receptor (Lepr), and platelet-derived growth factor receptor (PDGFR) (Morikawa et al., 2009; 
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Ding et al., 2012; Ding and Morrison, 2013; Zhou et al., 2014,). Imaging studies of the bone 
marrow niche consistently demonstrate that HSCs preferentially reside in close proximity to 
sinusoids surrounded by MSCs (Kiel et al., 2005; Sugiyama et al., 2006; Nombela-Arrieta et al., 
2013; Acar et al., 2015; Chen et al., 2016). MSCs have higher expression of key HSC-
supporting cytokines stem cell factor (Scf) and Cxcl12 compared to other cell types in the bone 
marrow, supporting the idea that MSCs are important sources for HSC regulation (Ding et al., 
2012; Ding and Morrison, 2013). Furthermore, conditional deletion of Scf or Cxcl12 from MSCs 
using Lepr-cre or Prx1-cre causes a dramatic loss of HSCs from the bone marrow (Ding et al., 
2012; Ding and Morrison, 2013; Greenbaum et al., 2013). In contrast, conditional deletion of Scf 
and Cxcl12 from osteoblasts did not cause HSC defects (Ding and Morrison, 2013). Thus, 
MSCs are considered a critical component of the HSC bone marrow niche.  
Although much progress has been made regarding the cellular components of the adult 
HSC niche, how the niche is established and regulated in the bone marrow is not completely 
understood. The limb bone marrow environment is largely derived from embryonic 
undifferentiated Prx1+ progenitor cells. These cells give rise to all of the mesenchymal tissue of 
the limb, including bone, fat, cartilage, tendons, synovial cells and MSCs (Akiyama et al., 2005; 
Kawanami et al., 2009; Sanchez-Gurmaches et al., 2015). Transplantation of developing 
progenitor MSCs at E14.5 into recipient kidney capsules results in the formation of ectopic bone 
marrow with recipient HSCs, demonstrating that these cells are capable of generating all 
necessary mesenchymal components of the HSC niche (Chan et al., 2009). In adulthood, LepR+ 
MSCs are largely quiescent, but can differentiate to osteoblasts and adipocytes to regenerate 
the niche during aging and after fracture or irradiation (Zhou et al., 2014). This population, which 
can also be identified by expression of PDGFRα, includes the vast majority of cells in the bone 
marrow that have characteristics of mesenchymal stem/progenitor cells (Morikawa et al., 2009). 
Interestingly, deletion of transcription factor Foxc1 from MSCs using Prx1-cre shifted the 
balance of MSC differentiation towards greater adipogenesis and caused a dramatic loss of 
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bone marrow cellularity and HSCs (Omatsu et al., 2014). In contrast, loss of Ebf3 from MSCs 
using Prx1-cre caused the opposite effect, inducing increased osteogenesis over adipogenesis 
(Seike et al., 2018). This led to osteosclerosis, loss of the bone marrow cavity, and loss of HSCs 
(Seike et al., 2018). In both cases, balanced regulation of MSC differentiation is required for 
maintaining functional HSCs. However, there is still little known about the underlying 
mechanisms regulating niche formation and maintenance.  
From intrinsic cellular programs to environmental cues, the mechanisms controlling 
when and how HSCs are activated to differentiation and self-renewal from quiescence are not 
fully understood. It is likely that additional novel regulation also influences HSC function. 
EPITRANSCRIPTIONAL REGULATION BY N6-METHYLADENOSINE 
m6A is a modified adenosine found in RNA and is one of the most abundant mRNA 
modifications in eukaryotic cells (Meyer and Jaffrey, 2014). While discovered in 1974 
(Desrosiers, Friderici and Rottman, 1974; Perry and Kelley, 1974), m6A has only recently been 
appreciated to have important roles in target mRNA regulation and gene expression. m6A RNA 
methylation is controlled by a dynamic system involving a methyltransferase complex that adds 
m6A to target transcripts, demethylases that remove m6A modification, and m6A-binding 
proteins that regulate target RNA metabolism. Through its effects on target transcripts, m6A has 
been shown to regular fundamental cellular processes and the study of m6A has opened up a 
new field of understanding gene expression regulation by post-transcriptional RNA 
modifications, or “epitranscriptional” regulation (Meyer et al., 2012).   
The m6A methyltransferase complex is composed of several known proteins: 
methyltransferase-like 3 (METTL3), methyltransferase-like 14 (METTL14), Wilms-tumor 
associated protein (WTAP), RNA binding motif protein 15 (RBM15), and several other 
accessory proteins. METTL3 is thought to be the only catalytically active component of the 
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complex, as Mettl3 knock-out cells display near complete loss of m6A (Geula et al., 2015). 
METTL14 was initially thought to be a methyltransferase, but was later shown to have no 
enzymatic activity (Sledz and Jinek, 2016). METTL14 is now recognized to have a crucial non-
catalytic role forming a heterodimer with METTL3, which stabilizes and increases METTL3’s 
activity (Liu et al., 2014; Wang et al., 2016). WTAP also binds to METTL3 and METTL14 and is 
crucial in their localization to nuclear speckles enriched in pre-mRNA machinery (Ping et al., 
2014). Localization to specific RNA targets is thought to be partially mediated through RBM15, 
which directly binds to METTL3 (Patil et al., 2016). There are also other recently identified m6A 
methyltransferases, including methyltransferase-like 16 (METTL16) and ZCCHC4, that are 
capable of writing m6A on small nuclear RNAs, ribosomal RNAs, and specific subsets of 
mRNAs, but their contribution to the m6A epitranscriptome is thought to be minor (Pendelton et 
al., 2017; Ma et al., 2019). 
Several groups have identified m6A modified mRNA targets transcriptome-wide in 
different cell types by using m6A-specific antibodies to immunoprecipitate (IP) and sequence 
m6A-modified RNA (Dominissini et al., 2013; Meyer et al., 2012). Through such studies, an m6A 
consensus sequence has been identified:	DRACH, where D=A, G or U and H=A, C or U. 
However, the presence of a consensus sequence does not ensure that a given adenosine will 
be methylated. Sequencing studies have shown that m6A is found predominantly near stop 
codons, long internal exons, and 3’ untranslated regions (Dominissini et al., 2013; Meyer et al., 
2012). Exactly how these sites are determined is still unknown.   
m6A modification has been shown to affect many aspects of target mRNA metabolism 
including alternative splicing, transcript stability, nuclear export, translation efficiency, and 
secondary RNA structure (Meyer and Jaffrey, 2014). These effects are thought to be mediated 
through m6A-binding or “reader” proteins. These include the YTH (YT521-B homology) domain 
family and domain containing proteins YTHDF1-3 and YTHDC1-2, insulin- like growth factor 2 
mRNA-binding proteins IGF2BP1–3, and heterogeneous nuclear ribonucleoproteins HRNPC, 
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HRNPG, and HRNPA2B1 (reviewed in Shi et al., 2019). Different readers have been associated 
with different effects on target RNA processing, including often conflicting functions. For 
example, IGF2BP proteins and YTHDC2 are thought to stabilize m6A targets, increasing their 
gene expression (Huang et al., 2018; Hsu et al., 2017). In contrast, YTHDF2 is thought to 
decrease m6A target expression by localizing targets to RNA decay processing bodies, 
promoting their degradation (Wang et al., 2014). Other studies suggest that m6A targets are 
regulated not at the mRNA level, but at the protein level through effects on translation efficiency 
by YTHDF1 or m6A-independent functions of METTL3 itself (Wang et al., 2015; Lin et al., 2016). 
These discrepancies may be due to differences in the studied cell types or environments and 
illustrate that m6A regulation may have different functions depending upon the biologic context, 
such as variations in m6A-binding proteins or m6A targets within a cell. This notion of context-
dependent roles for m6A is consistent with m6A profiling of 21 different human fetal tissues 
(including brain, heart kidney, lung, and liver) that demonstrated that while the majority of m6A 
targets are conserved, there are also tissue-specific m6A targets (Xiao et al., 2019).  Tissue and 
cell type-specific methylation patterns may also suggest the possibility that m6A can regulate 
cell type-specific processes. 
Through effects on target RNA metabolism, m6A-mediated regulation has proven to be 
critical to fundamental cellular processes such as DNA damage repair (Xiang et al., 2017), 
meiosis (Agarwala et al., 2012), circadian periods (Fustin et al., 2013), and cell fate (Aguilo et 
al., 2015; Batista et al., 2014; Chen et al., 2015; Guela et al., 2015; Wang, et al., 2014). Induced 
pluripotent stem cells, embryonic stem cells, and neural stem cells all have m6A modified 
transcripts of genes implicated in controlling cell fate, suggesting that m6A regulates cell fate 
determination (Batista et al., 2014; Wang, et al., 2014; Aguilo et al., 2015; Chen et al., 2015; 
Guela et al., 2015). Consistent with this notion, loss of Mettl3 prevents embryonic stem cell 
transition from self-renewal to differentiation (Batista et al., 2014, Geula et al., 2015). Similarly, 
deletion of Mettl14 in embryonic neural progenitors using Nestin-cre causes differentiation 
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defects (Wang et al., 2018). These results demonstrate that METTL3 and m6A modification 
regulate differentiation processes in different types of stem cells, and raises the possibility that 
m6A might also regulate cell fate in HSCs.  
 
N6-METHYLADENOSINE IN HEMATOPOIESIS 
 
The role of m6A in hematopoiesis has only begun to be explored. The first direct 
connection between m6A and hematopoiesis came from investigations of hematopoietic 
development. Mettl3-deficient morphant zebrafish embryos have defects in endothelial-to-
hematopoietic transition (EHT), the process for emergence of early hematopoietic 
stem/progenitor cells (HSPCs) from the hemogenic endothelium during development (Zhang et 
al., 2017). Consequently, the Mettl3-deficient embryos retain endothelial identity markers in the 
hemogenic endothelium and have reduced HSPCs (Zhang et al., 2017). This reduction in HSPC 
emergence was also recapitulated in Vecadherin-cre; Mettl3fl/fl mouse embryos, in which Mettl3 
deleted from endothelial cells of the aorta-gonad-mesonephros (Lv et al., 2018). While these 
early developmental HSPCs do not have reconstitution potential in transplantation, a 
requirement for definitive HSCs, this work demonstrates that m6A impacts HSC emergence.  
The role for m6A has also been investigated in more mature hematopoietic cells. Human 
CD34+ cord-blood cells, a mixed hematopoietic stem and progenitor population, transduced with 
Mettl3 shRNA have reduced colony forming capacity and increased myeloid differentiation in 
culture (Vu et al., 2017). Conditional deletion of Mettl3 from naïve T cells using Cd4-cre 
prevents proliferation and differentiation of naïve T cells, largely attributed to inhibition of T cell 
activation from loss of m6A-mediated decay of SOCS genes (Li et al., 2017).   
There is also evidence that m6A plays a role in hematopoietic diseases. Multiple 
members of the m6A pathway, including Mettl3, Mettl14, Wtap and Rbm15, are highly expressed 
in myeloid leukemia compared to other types of cancers (Vu et al., 2017; Jaffery and Kharas, 
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2017). Mettl3 knock-down by shRNA or CRISPR-Cas9 in acute myeloid leukemia cell lines 
caused higher expression of differentiation markers, reduced proliferation and reduced colony 
formation in culture (Barbieri et al., 2017; Vu et al., 2017). Furthermore, immunodeficient mice 
transplanted with Mettl3-depleted leukemic cells showed delayed leukemia development and 
better survival, suggesting that m6A is involved in myeloid leukemia progression and 
differentiation (Barbieri et al., 2017; Vu et al., 2017). Myc was found to be a highly methylated 
m6A target in leukemia cells in multiple studies (Weng et al., 2017; Vu et al., 2017; Su et al., 
2018). After Mettl3 depletion, leukemia cells display reduced MYC protein levels that are 
thought to partially explain their altered cell fate (Barbieri et al., 2017; Vu et al., 2017; Su et al., 
2018). As MYC is known to be a master regulator of differentiation in cancer and in normal 
HSCs, it is possible that Myc regulation by m6A may also influence HSC function.  
A common theme has emerged from these studies: METTL3 and m6A are required in 
cell fate transition, and specifically differentiation rather than self-renewal, in multiple 
hematopoietic cell types, normal or pathologic. However, whether this influences adult HSC 
regulation was unknown. It is possible that m6A modification influences HSC self-renewal, 
differentiation, quiescence, and/or survival. m6A might also play a role in the regulation of MSC 
cell fate, thus impacting extrinsic regulation of HSCs in the bone marrow niche. Within the 
following chapters, I explore these ideas, looking at m6A within HSCs in Chapter 2 and within 
MSCs in Chapter 3. Determining how RNA epitranscription impacts HSCs, both cell-intrinsically 
and –extrinsically, provides a new angle for understanding HSC function and may provide a new 
approach for developing tools to manipulate HSC function and new therapies for bone marrow 
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Hematopoietic stem cells (HSCs) maintain balanced self-renewal and differentiation, but 
how these functions are precisely regulated is not fully understood. N6-methyladenosine (m6A) 
mRNA methylation has emerged as an important mode of epitranscriptional gene expression 
regulation affecting many biological processes. We show that deleting the m6A 
methyltransferase, Mettl3, from the adult hematopoietic system led to an accumulation of HSCs 
in the bone marrow and marked reduction of reconstitution potential due to a blockage of HSC 
differentiation. Interestingly, deleting Mettl3 from myeloid cells using Lysm-cre did not impact 
myeloid cell number or function. m6A sequencing revealed 2,073 genes with significant m6A 
modification in HSCs. Myc was identified as a direct target of m6A in HSCs. Mettl3-deficient 
HSCs failed to up-regulate MYC expression upon stimulation to differentiate and enforced 
expression of Myc rescued differentiation defects of Mettl3-deficient HSCs. Our results revealed 




HSCs give rise to all blood cells, and are characterized by their ability for life-long self-
renewal and multi-lineage differentiation. HSC function is regulated by complex cell-intrinsic and 
-extrinsic pathways (reviewed in Rossi et al., 2012; Morrison and Scadden, 2014), but the 
mechanisms that control balanced self-renewal and differentiation are poorly understood. 
Transcriptional, translational and epigenetic regulators have been shown to critically regulate 
HSC function (reviewed in Rossi et al., 2012). Whether other molecular mechanisms also 




m6A is a modified base found in eukaryotic mRNAs (Desrosiers, Friderici and Rottman, 
1974). This modification of adenosine is abundant and functions as an epitranscriptomic 
regulator of target mRNAs through multiple mechanisms, including stability and translation 
efficiency (reviewed in Meyer and Jaffrey, 2017). m6A is deposited onto mRNAs by a 
methyltransferase complex, composed of methyl transferase-like 3 (METTL3), methyl 
transferase-like 14 (METTL14) and Wilms-tumor associated protein (WTAP) and other 
accessory proteins (reviewed in Meyer and Jaffrey, 2017). METTL3 is the essential catalytic 
component of the complex (Geula et al., 2015; Sledz et al., 2016; Wang, Doxtader and Nam, 
2016; Wang et al., 2016). m6A has been shown to impact fundamental cellular processes, 
including DNA damage repair (Xiang et al., 2017), meiosis (Agarwala et al., 2012), and 
circadian clock (Fustin et al., 2013). Transcriptome-wide mapping of m6A modification has 
revealed cell type-specific methylation targets, suggesting that m6A regulates cell type-specific 
processes (Chen et al., 2015).  
Interestingly, m6A has been shown to impact stem and progenitor cell fate. Disruption of 
the m6A pathway blocks the decay of naïve embryonic stem cell program (Geula et al., 2015; 
Batista et al., 2014). m6A also plays a critical role in embryonic neurogenesis by regulating fetal 
neural stem and progenitor cells (Yoon et al., 2017; Wang et al., 2018). The role of m6A in the 
hematopoietic system is emerging. Using zebrafish as a model, it has been shown that m6A is 
required for endothelial to hematopoietic transition and the emergence of hematopoietic stem 
and progenitor cells (Zhang et al., 2017). shRNA knockdown of Mettl3 or Mettl14 in human 
hematopoietic stem and progenitor cells leads to myeloid differentiation in vitro (Vu et al., 2017; 
Weng et al., 2017). These studies show that m6A plays critical roles for HSC emergence and in 









Deletion of Mettl3 disrupts hematopoiesis and leads to accumulation of HSCs 
We performed quantitative real-time PCR (qPCR) analysis to assess the expression of 
Mettl3 in the hematopoietic system. Mettl3 transcripts were expressed at approximately 4.5-fold 
higher levels in CD150+CD48-Lin-Sca1+cKit+ HSCs compared with whole bone marrow cells 
(Figure 2.1a), suggesting that METTL3-mediated m6A may regulate the function of HSCs.  
To test whether m6A regulates HSCs and hematopoiesis in vivo, we generated and 
validated a floxed allele of Mettl3 (Figure 2.1b), and crossed it with Mx1-cre (Kuhn et al., 1995) 
to generate Mx1-cre; Mettl3fl/fl mice. We conditionally deleted Mettl3 from the adult 
hematopoietic cells by intraperitoneally injecting polyinosinic-polycytidylic acid (pIpC) into 6-8 
week old Mx1-cre; Mettl3fl/fl mice (Figure 2.1b). Efficient deletion in HSCs was achieved by 10 
days after the last pIpC injection (Figure 2.1c-d). Ten to 14 days (short term) after the last pIpC 
injection, complete blood count analyses revealed a significant decrease in platelet count, but 
not white or red blood cell counts, in Mx1-cre; Mettl3fl/fl mice compared with pIpC-treated 
controls (Figure 2.2a-c). Recent work in the field has proposed that platelets can be directly 
generated from HSCs (Rodriguez-Fraticelli et al., 2018; Carrelha et al., 2018). The platelet 
phenotype raises the possibility that m6A may regulate HSCs. The same phenotype persisted 2-
3 months after the last pIpC injection (Figure 2.2a-c). By 4 months, white blood cell counts were 
also significantly reduced, with an altered white blood cell distribution (Figure 2.2a and Figure 




Figure 2.1 Mettl3 is efficiently deleted from HSCs in Mx1-cre; Mettl3fl/fl mice after Cre 
induction. 
(a) qPCR analysis of Mettl3 mRNA expression in wild-type bone marrow populations. (n=7 for 
WBM, n=6 for LSK, n=10 for HSC, n=6 for MPP, n=6 for LMPP, n=6 for CLP, n=4 for MEP, n=4 
for CMP, n=3 for GMP, n=10 for Gr1+Mac1+).  
(b) Schematic of Cre-mediated recombination of Mettl3fl allele (left) and Mx1-cre; Mettl3fl/fl pIpC 
treatment schedule (right).  
(c) Representative genotyping results of colonies formed by single sorted HSCs after pIpC 
treatment. The majority of colonies show complete deletion, with rare colonies showing deletion 
of only one Mettl3 allele. Experiment was repeated with biologically independent samples three 
times with similar results.  
(d) qPCR analysis of Mettl3 mRNA expression in HSCs from pIpC-treated control and Mx1-cre; 
Mettl3fl/fl mice (n=4 for control, n=5 for Mx1-cre; Mettl3fl/fl).  
All samples are from biologically independent animals. Values are shown as individual 












































































































Deletion of Mettl3 led to a significant reduction in bone marrow cellularity (Figure 2.2d), 
but not spleen cellularity 10-14 days after the last pIpC injection (Figure 2.3b). However, by 2-4 
months after the last pIpC injection, in addition to a significant bone marrow cellularity reduction, 
the spleen size and cellularity were significantly increased with a distortion of cell type 
distribution (Figure 2.2e and Figure 2.3b-c). The spleens contained more HSCs in Mx1-cre; 
Mettl3fl/fl mice compared with controls (Figure 2.2f). These data are suggestive of 
extramedullary hematopoiesis after loss of m6A. 
In the bone marrow, Lin-Sca1+cKit+ (LSK) hematopoietic progenitors (Figure 2.2g) and 
HSCs (Figure 2.2h-j) were significantly increased at all time points examined. The HSC pool 
uniquely expanded over time from 10-14 days to 4 months after the last pIpC injection: 
progressing from a 3-fold to a 17-fold increase in HSC frequency (Figure 2.2h-j). In contrast, 
CD150-CD48-LSK MPP frequency was not significantly increased while CD150-CD48+LSK 
progenitor frequency was only modestly increased (Figure 2.2k and Figure 2.3e). 
CD150+CD48+LSK megakaryocyte-skewed multipotent progenitor frequency was significantly 
increased (Figure 2.3f), suggesting that there is also an effect on the megakaryocyte lineage. 
Thus, at the top of the hematopoietic hierarchy, loss of m6A preferentially leads to HSC 
accumulation.  
We also examined other hematopoietic progenitors in the bone marrow. These included 
Lin-Sca1lowcKitlowFlt3+IL7Ra+ common lymphoid progenitors (CLPs), CD34+FcgR-Lineage-Sca1-
cKit+ common myeloid progenitors (CMPs), CD34+FcgR+Lineage-Sca1-cKit+ 
granulocyte/macrophage progenitors (GMPs), and CD34-FcgR-Lineage-Sca1-cKit+ 
megakaryocytic/erythroid progenitors (MEPs). The frequencies of these hematopoietic 
progenitors were unchanged in Mx1-cre; Mettl3fl/fl mice compared with controls until 4 months 
after the last pIpC treatment, when there was a modest decrease in GMP and a modest 
increase in MEP frequencies (Figure 2.3g). There was a significant increase in Lin-Sca1-
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cKit+CD150+CD41+ megakaryocyte progenitors and CD41+ megakaryocytic cells in the bone 
marrow (Figure 2.3h-i), suggesting that the reduction in platelet counts (Figure 2.2b) is due to 
a differentiation defect in the megakaryocyte lineage. These data suggest that loss of Mettl3 
preferentially impacts HSCs, with effects on the megakaryocyte lineage. 
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Figure 2.2 Loss of Mettl3 leads to accumulation of HSCs and perturbed hematopoiesis. 
(a - c) White blood cell (a), platelet (b), and red blood cell counts (c) from pIpC-treated control 
and Mx1-cre; Mettl3fl/fl mice (n=7 for control (10-14d), n=7 for Mx1-cre; Mettl3fl/fl (10-14d), n=4 
for control (2-3m), n=4 for Mx1-cre; Mettl3fl/fl (2-3m), n=3 for control (4m), n=4 for Mx1-cre; 
Mettl3fl/fl (4m)).  
(d) Bone marrow cellularity per hindlimb (n=8 for control (10-14d), n=8 for Mx1-cre; Mettl3fl/fl (10-
14d), n=5 for control (2-3m), n=6 for Mx1-cre; Mettl3fl/fl (2-3m), n=4 for control (4m), n=4 for 
Mx1-cre; Mettl3fl/fl (4m)). 
(e) Representative images of the spleens from Mx1-cre; Mettl3fl/fl and control mice 10 days and 
3 months after pIpC treatment, as indicated. 
(f) Splenic HSC frequency (n=6 for control (10-14d), n=5 for Mx1-cre; Mettl3fl/fl (10-14d), n=6 for 
control (2-3m), n=6 for Mx1-cre; Mettl3fl/fl (2-3m), n=4 for control (4m), n=4 for Mx1-cre; Mettl3fl/fl 
(4m)).  
(g) Frequencies of bone marrow Lin-Sca-1+c-Kit+ (LSK) progenitors (n=7 for control (10-14d), 
n=6 for Mx1-cre; Mettl3fl/fl (10-14d), n=6 for control (2-3m), n=7 for Mx1-cre; Mettl3fl/fl (2-3m), n=4 
for control (4m), n=4 for Mx1-cre; Mettl3fl/fl (4m)).  
(h) Frequency of bone marrow HSCs (n=7 for control (10-14d), n=6 for Mx1-cre; Mettl3fl/fl (10-
14d), n=6 for control (2-3m), n=7 for Mx1-cre; Mettl3fl/fl (2-3m), n=4 for control (4m), n=4 for 
Mx1-cre; Mettl3fl/fl (4m)).  
(i) Bone marrow HSCs per hindlimb (n=7 for control (10-14d), n=6 for Mx1-cre; Mettl3fl/fl (10-
14d), n=5 for control (2-3m), n=6 for Mx1-cre; Mettl3fl/fl (2-3m), n=4 for control (4m), n=4 for 
Mx1-cre; Mettl3fl/fl (4m)). 
(j) Fold increase in Mx1-cre; Mettl3fl/fl bone marrow HSC or MPP frequency compared to 
littermate control frequencies at indicated times after pIpC treatment (n=6 (10-14d), n=7 (2-3m), 
n=4 (4m)).  
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(k) Bone marrow CD150-CD48-LSK MPP frequencies (n=6 for control (10-14d), n=6 for Mx1-
cre; Mettl3fl/fl (10-14d), n=6 for control (2-3m), n=7 for Mx1-cre; Mettl3fl/fl (2-3m), n=4 for control 
(4m), n=4 for Mx1-cre; Mettl3fl/fl (4m)). 
All samples are from biologically independent mice. Values are shown as individual points with 
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Figure 2.3 Mx1-cre; Mettl3fl/fl mice have defective hematopoiesis. 
(a) White blood cell count differential for control and Mx1-cre; Mettl3fl/fl mice 4 months after pIpC 
treatment (n=3 for control, n=4 for Mx1-cre; Mettl3fl/fl). 
(b) Spleen cellularity (n=8 for control (10-14d), n=8 for Mx1-cre; Mettl3fl/fl (10-14d), n=5 for 
control (2-3m), n=6 for Mx1-cre; Mettl3fl/fl (2-3m), n=4 for control (4m), n=4 for Mx1-cre; Mettl3fl/fl 
(4m)). 
(c) Frequency of cell populations in the spleens of Mx1-cre; Mettl3fl/fl mice at least 14 days after 
pIpC treatment with prominent splenomegaly compared to controls (n=5 for control, n=5 for 
Mx1-cre; Mettl3fl/fl, , except LSK n=4 for control, n=4 for Mx1-cre; Mettl3fl/fl ). 
(d) Representative flow cytometric plots of Lin- gated and LSK gated bone marrow cells stained 
for the indicated cell surface markers. Numbers represent the population frequencies among 
single live bone marrow cells. 
(e) Bone marrow CD150-CD48+LSK progenitor frequencies (n=5 for control (10-14d), n=5 for 
Mx1-cre; Mettl3fl/fl (10-14d), n=5 for control (2-3m), n=6 for Mx1-cre; Mettl3fl/fl (2-3m), n=4 for 
control (4m), n=4 for Mx1-cre; Mettl3fl/fl (4m)). 
(f) Bone marrow CD150+CD48+LSK progenitor frequencies (n=5 for control (10-14d), n=5 for 
Mx1-cre; Mettl3fl/fl (10-14d), n=5 for control (2-3m), n=6 for Mx1-cre; Mettl3fl/fl (2-3m), n=4 for 
control (4m), n=4 for Mx1-cre; Mettl3fl/fl (4m)). 
(g) Frequencies of bone marrow progenitor populations. CLP, common lymphoid progenitor; 
CMP, common myeloid progenitors; GMP, granulocyte–monocyte progenitors; MEP, 
megakaryocyte–erythroid progenitors; LMPP, lymphoid-primed multipotent progenitors (n=4 for 
control (10-14d), n=4 for Mx1-cre; Mettl3fl/fl (10-14d), n=5 for control (2-3m), n=6 for Mx1-cre; 
Mettl3fl/fl (2-3m), n=4 for control (4m), n=4 for Mx1-cre; Mettl3fl/fl (4m)). 
(h) Frequency of megakaryocyte progenitors (Lineage-Sca1-cKit+CD150+CD41+) cells in the 




(i) Frequencies of mature cell populations in the bone marrow (n=4 for control (10-14d), n=4 for 
Mx1-cre; Mettl3fl/fl (10-14d), n=5 for control (2-3m), n=5 for Mx1-cre; Mettl3fl/fl (2-3m), n=4 for 
control (4m), n=4 for Mx1-cre; Mettl3fl/fl (4m)). 
(j) 2’-7’-dichlorofluorescein diacetate (DCFDA) staining (ROS levels) by flow cytometry in HSCs 
2-3 months after pIpC treatment (n=3 for control, n=3 for Mx1-cre; Mettl3fl/fl). 
(k) γH2AX staining by flow cytometry in HSCs 2-3 months after pIpC treatment (n=3 for control, 
n=3 for Mx1-cre; Mettl3fl/fl). 
All samples were from biologically independent animals. Values are shown as individual points 
with mean ± s.d. In (h) and (i), normalized geometric mean fluorescence intensity (MFI ± s.d.) 








































































































































































































































































































































































































































































































































































Deletion of Mettl3 preferentially blocks HSC differentiation 
HSCs from pIpC-injected Mx1-cre; Mettl3fl/fl mice did not incorporate more BrdU (Figure 
2.4a), but underwent slightly more cell death (Figure 2.4b), suggesting that the accumulation of 
HSCs may be the result of blocked differentiation rather than enhanced self-renewal. The 
Mettl3-deficient HSCs did not have elevated levels of reactive oxygen species (ROS) or γH2Ax 
staining (Figure 2.3h-i). Consistent with an HSC differentiation defect, pIpC-injected Mx1-cre; 
Mettl3fl/fl mice had worse survival compared to controls when challenged with a myeloablative 
agent, 5-fluorouracil (5FU) (Figure 2.4c). 
To directly assess the differentiation potential of Mettl3-deficient HSCs, we performed 
methylcellulose assays. Single HSCs from pIpC-treated Mx1-cre; Mettl3fl/fl or control mice were 
directly sorted into methylcellulose, which supports myelo-erythroid differentiation in vitro (Ding 
et al., 2012; Ding and Morrison, 2013). Significantly fewer Mettl3-deficient HSCs formed 
colonies compared with control HSCs, particularly multipotent granulocyte, erythrocyte, 
monocyte and megakaryocyte (GEMM) colonies (Figure 2.4d). The vast majority of the colonies 
formed by Mettl3-deficient HSCs were significantly smaller compared with those formed by 
control HSCs (Figure 2.4e-f). Flow cytometric analysis on cells from these colonies showed that 
Mettl3-deficient HSCs failed to differentiate while control HSCs readily differentiated into Gr1+ 
and Mac1+ myeloid cells (Figure 2.4g-i). A few colonies were formed at normal sizes by Mettl3-
deficient HSCs and genotyping revealed that these colonies had escaped complete Mettl3 
deletion (Figure 2.4j-k). Mettl3-deficient HSCs in the spleens also failed to differentiate (Figure 
2.5a). 
In contrast, when Mettl3-deficient whole bone marrow cells were plated into 
methylcellulose, colonies formed at similar numbers, size and types compared with controls 
(Figure 2.5b). We further plated sorted Mettl3-deficient restricted progenitors (LSK, CD150-
CD48+LSK and CD150+CD48+LSK), into methylcellulose. They formed normal numbers of 
colonies, similar in size and type compared with controls (Figure 2.5c). Flow cytometry analysis 
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confirmed that these colonies contained normal numbers of differentiated cells (Figure 2.5d). 
Taken together, these data suggest that loss of Mettl3 preferentially leads to a differentiation 




Figure 2.4 Mettl3 is essential for adult HSC differentiation in vitro. 
(a) Frequency of BrdU+ HSCs 10-14 days after pIpC treatment (n=4 for control, n=4 for Mx1-cre; 
Mettl3fl/fl). 
(b) Frequency of DAPI- AnnexinV+ HSC, MPP and LSK populations 10-14 days after pIpC (n=6 
for control, n=6 for Mx1-cre; Mettl3fl/fl). 
(c) Kaplan-Meyer survival analysis of control and Mx1-cre; Mettl3fl/fl mice treated with weekly 5-
FU injections 10 days after the last dose of pIpC. P value by log-rank test (n=4 for control, n=4 
for Mx1-cre; Mettl3fl/fl). 
(d) Frequencies of colony formation from single sorted HSCs. Colony-forming units (CFU) 
scored as granulocyte, erythroid, macrophage, megakaryocyte (GEMM), granulocyte, 
macrophage (GM), megakaryocyte (Mk), or erythrocyte (E) colonies (n=7 for control, n=7 for 
Mx1-cre; Mettl3fl/fl). 
(e) Representative image of CFU-GM from single HSCs from control (left) and Mettl3-deleted 
(right) single HSCs, genotypes confirmed by PCR. Scale bars are 400um. 
(f) The proportion of large colonies (estimated >5,000 cells) out of all colonies formed from 
HSCs (n=6 for control, n=6 for Mx1-cre; Mettl3fl/fl) or LSK cells (n=6 for control, n=6 for Mx1-cre; 
Mettl3fl/fl). 
(g) Representative flow cytometric histograms of mature myeloid cell surface markers Gr-1 and 
Mac-1 on HSC-derived colony cells from pIpC-treated control and Mx1-cre; Mettl3fl/fl mice.  
(h-i) Quantification of expression of Gr-1 (h) and Mac-1 (i) cell surface markers on HSC and 
LSK colony cells by flow cytometry (HSC n=8 for control, n=6 for Mx1-cre; Mettl3fl/fl ; LSK n=6 for 
control, n=6 for Mx1-cre; Mettl3fl/fl). 
(j) Representative images of colonies from control and Mx1-cre; Mettl3fl/fl LSK cells. Experiment 




(k) Representative genotyping image of colonies formed by single HSCs grouped by size. 
Experiment was repeated four times from biologically independent animals with similar results.  
All samples are from biologically independent animals. Values are shown as individual points 

































































































































































































Figure 2.5 HSCs preferentially require Mettl3 compared to other hematopoietic 
progenitors for differentiation in vitro. 
(a) Quantification of the frequency of Gr1+ and Mac1+ cells by flow cytometry on colony cells 
from splenic HSCs in Mx1-cre; Mettl3fl/fl mice at least 14 days after pIpC treatment with 
prominent splenomegaly compared to controls (n=5 for control, n=5 for Mx1-cre; Mettl3fl/fl). 
(b) Numbers of colonies formed from 10,000 bone marrow cells, scored as CFU-GEMM, CFU-
GM, CFU-E, or CFU-MK (n=4 for control, n=4 for Mx1-cre; Mettl3fl/fl). 
(c) Number of colonies formed from control and Mx1-cre; Mettl3fl/fl cells of the indicated 
populations 10 days after pIpC treatment. 200 LSK cells, 50 MPP cells, 24 CD150-CD48+LSK 
and 24 CD150+CD48+LSK cells were plated per experiment. (For LSK and MPP: n=4 for control, 
n=4 for Mx1-cre; Mettl3fl/fl; for CD150-CD48+LSK and CD150+CD48+LSK: n=3 for control, n=3 for 
Mx1-cre; Mettl3fl/fl). 
(d) Quantification of the frequency of Gr1+ and Mac1+ cells by flow cytometry on colony cells 
from the indicated cell populations from mice 10 days after pIpC treatment. (MPP: n=7 for 
control, n=7 for Mx1-cre; Mettl3fl/fl; CD150-CD48+LSK: n=10 for control, n=8 for Mx1-cre; 
Mettl3fl/fl; CD150+CD48+LSK: n=7 for control, n=6 for Mx1-cre; Mettl3fl/fl;). 
All samples are from biologically independent animals. Values are shown as individual points 
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Deletion of Mettl3 leads to cell-intrinsic HSC reconstitution and differentiation defects in 
vivo 
To test whether loss of Mettl3 leads to HSC defects in vivo, we performed competitive 
reconstitution assays by transplanting 500,000 bone marrow cells from Mx1-cre; Mettl3fl/fl or 
control mice 10 days after the last pIpC injection along with 500,000 wild-type competing bone 
marrow cells into lethally irradiated recipient mice. Mettl3-deficient bone marrow cells 
contributed significantly lower levels of overall, myeloid, B and T lineage cells in the peripheral 
blood and a trend towards lower levels of HSCs in the bone marrow compared with controls 
(Figure 2.6a and Figure 2.7a). Genotyping analysis on sorted residual donor-derived peripheral 
blood cells demonstrated that these residual cells escaped complete Mettl3 deletion (Figure 
2.7b). To specifically test whether HSCs were functionally defective, we sorted and transplanted 
Mettl3-deficient and control HSCs along with wild-type competing bone marrow cells into lethally 
irradiated mice. While control HSCs readily reconstituted the recipient mice in all major 
hematopoietic lineages, Mettl3-deficient HSCs failed to give any discernable reconstitution 
(Figure 2.6b and Figure 2.7c). These data suggest that Mettl3-deficient HSCs are defective in 
reconstituting recipient mice.  
To determine whether Mettl3 is required cell-intrinsically for HSC function, we 
transplanted Mx1-cre; Mettl3fl/fl or control bone marrow cells, without pIpC treatment, along with 
wild-type competitor bone marrow cells into irradiated recipient mice. We waited at least 8 
weeks after transplantation for stable bone marrow chimerism to be established. Mettl3 was 
then deleted by pIpC injection and donor-derived peripheral blood cells were monitored over 
time. Overall reconstitution by Mettl3-deficient bone marrow cells was significantly lower than 
controls (Figure 2.6c). The reconstitution defects were mainly in the myeloid and B lineages, 
but not in the T cell lineages (Figure 2.6c), consistent with the slow turnover kinetics of T cells 
in adults in vivo. After 16 weeks, the recipient mice were sacrificed and analyzed for the 
frequencies of donor-derived bone marrow HSCs and hematopoietic progenitors. Mettl3-
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deficient HSCs were present at similar levels compared with control HSCs (Figure 2.6d), 
suggesting that HSC self-renewal is largely normal. However, these HSCs generated gradually 
less mature hematopoietic cells along the differentiation hierarchy (Figure 2.6d). Consistent 
with the depletion of donor-derived myeloid cells in the peripheral blood (Figure 2.6c), very little 
CMPs, GMPs and MEPs were derived from Mettl3-deficient HSCs (Figure 2.6d). Genotyping on 
sorted donor-derived cells in recipient mice showed that these residual cells escaped complete 
Mettl3 deletion (Figure 2.7d). These data suggest that Mettl3 is required for HSC differentiation 
in vivo. 
We also conditionally deleted Mettl3 from hematopoietic cells using Rosa26-creER25. 
We noncompetitively transplanted bone marrow cells from Rosa26-creER; Mettl3fl/fl mice into 
irradiated recipient mice and then deleted Mettl3 by administering tamoxifen. Deletion of Mettl3 
led to a significantly higher frequency of HSCs in the recipient mice (Figure 2.7e), recapitulating 
the Mx1-cre; Mettl3fl/fl model (Figure 2.2h). We also competitively transplanted Rosa26-creER; 
Mettl3fl/fl bone marrow cells together with recipient-type bone marrow cells and waited at least 8 
weeks after transplantation for stable bone marrow chimerism before administering tamoxifen. 
Tamoxifen-induced deletion of Mettl3 also led to a significant reduction in reconstitution activity 




Figure 2.6 Loss of Mettl3 disrupts HSC differentiation in vivo. 
(a) Competitive transplantation of 500,000 donor whole bone marrow cells from pIpC-treated 
Mx1-cre; Mettl3fl/fl or Mettl3fl/fl controls with 500,000 competitor cells. Multi-lineage chimera levels 
in the peripheral blood were assessed up to 16 weeks after transplantation (n=7 for control, n=8 
for Mx1-cre; Mettl3fl/fl; samples were from independent recipients of two independent donor pairs 
from two experiments). 
(b) Competitive transplantation of 50 sorted HSCs from pIpC-treated Mx1-cre; Mettl3fl/fl or 
controls with 300,000 competitor cells. Multi-lineage chimera levels in the peripheral blood were 
assessed up to 16 weeks after transplantation (n=9 for control, n=9 for Mx1-cre; Mettl3fl/fl; 
samples were from independent recipients of two independent donor pairs from two 
experiments). 
(c) 500,000 donor whole bone marrow cells from untreated Mx1-cre; Mettl3fl/fl or controls with 
500,000 competitor cells were transplanted into lethally irradiated recipient mice. Recipients 
were treated with pIpC after stable peripheral blood chimerism was established. Multi-lineage 
peripheral blood chimera levels shown as the percentage of the original chimera level up to 16 
weeks after pIpC treatment (n=11 for control, n=12 for Mx1-cre; Mettl3fl/fl; samples were from 
independent recipients of three independent donor pairs from three experiments). 
(d) Chimera levels of indicated bone marrow cell populations 20 weeks after pIpC treatment 
from (c) (n=9 for control, n=9 for Mx1-cre; Mettl3fl/fl; samples were from independent recipients 
of three independent donor pairs from three experiments). 
Values are shown as individual points with mean ± s.d. P values were determined by unpaired 
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Mettl3 is not required for myelopoiesis 
To directly test whether the observed predominant myeloid lineage reconstitution defect 
(Figure 2.6c) was a consequence of loss of Mettl3 in myeloid cells, we conditionally deleted 
Mettl3 from myeloid cells by generating Lysm-cre; Mettl3fl/fl mice. Consistent with previous 
reports (Clausen et al., 1999), Lysm-cre efficiently recombined in bone marrow myeloid cells 
(Figure 2.7g). Six to 8-week old Lysm-cre; Mettl3fl/fl mice had normal peripheral blood counts 
(Figure 2.7h and Figure 2.8a-b), normal bone marrow and spleen cellularity (Figure 2.7i and 
Figure 2.8c), and normal frequencies of myeloid cells in the bone marrow and spleens (Figure 
2.8d). 
Mettl3-deficient bone marrow myeloid cells from Lysm-cre; Mettl3fl/fl mice formed 
macrophages with normal morphology (Figure 2.7j). When challenged with lipopolysaccharide 
(LPS), these macrophages showed normal up-regulation of inflammatory cytokines, Tnfa, Il1b 
and Il6 (Figure 2.8e). Mettl3-deficient bone marrow-derived macrophages also displayed robust 
engulfing activity, similar to controls (Figure 2.8f). These data suggest that Mettl3 is not 
required for the maintenance or function of mature myeloid cells and the observed reconstitution 
deficiencies (Figure 2.6c) are a consequence of HSC differentiation defects. Furthermore, 
these data provide conclusive evidence that there is a stage-specific dependence on Mettl3 and 




Figure 2.7 HSCs, but not mature myeloid cells, require Mettl3 for function in vivo. 
(a) Chimera levels of bone marrow HSCs 16 weeks after transplantation from Fig. 3a (n=7 for 
control, n=6 for Mx1-cre; Mettl3fl/fl; samples were from independent recipients of two 
independent donor pairs from two experiments). 
(b) Representative genotyping images of Mx1-cre; Mettl3fl/fl donor-derived cells 20 weeks after 
transplantation from Fig. 3a showing incomplete deletion of Mettl3. Experiment was repeated 
twice with similar results. 
(c) Chimera levels of bone marrow HSCs 16 weeks after transplantation from Fig. 3b (n=9 for 
control, n=9 for Mx1-cre; Mettl3fl/fl ; samples were from independent recipients of two 
independent donor pairs from two experiments). 
(d) Representative genotyping images of Mx1-cre; Mettl3fl/fl donor-derived cells 12 weeks after 
pIpC treatment from Fig. 3c showing incomplete deletion of Mettl3. Experiment was repeated 
twice with similar results. 
(e) 1 million donor whole bone marrow cells from untreated Rosa26-CreER; Mettl3fl/fl or control 
mice were noncompetitively transplanted into lethally irradiated recipient mice. Recipients with 
peripheral blood chimerism of >90% were treated with tamoxifen (TAM) 6 weeks after the 
transplantation. The frequency of donor HSCs 8 weeks after TAM is shown (n=4 for control, n=3 
for Rosa26-CreER; Mettl3fl/fl ; samples were from independent recipients of two independent 
donor pairs from two experiments).  
(f) Schematic of experimental design (top). 500,000 donor whole bone marrow cells from 
untreated Rosa26-CreER; Mettl3fl/fl or control mice with 500,000 competitor cells were 
transplanted into lethally irradiated recipient mice. Recipients were treated with tamoxifen (TAM) 
6 weeks after the transplantation. Multi-lineage peripheral blood chimera levels are shown as 
the percentage of original chimera levels up to 16 weeks after TAM treatment (n=12 for control, 
n=11 for Rosa26-CreER; Mettl3fl/fl ; samples were from independent recipients of three 
independent donor pairs from three experiments). 
		
40 
(g) qPCR analysis of Mettl3 mRNA expression in cultured bone marrow macrophages (n=3 for 
control, n=3 for LysM-cre; Mettl3fl/fl). 
(h) Red blood cell and platelet peripheral blood counts (n=6 for control, n=6 for LysM-cre; 
Mettl3fl/fl). 
(i) Spleen cellularity (n=5 for control, n=5 for LysM-cre; Mettl3fl/fl). 
(j) Representative images of macrophages derived from control or LysM-cre; Mettl3fl/fl bone 
marrow. Experiment was repeated three times with similar results. Scale bars are 100um. 
All samples are from biologically independent animals. Values are shown as individual points 


































































































































































































































Figure 2.8 Loss of Mettl3 has no impact on myeloid cell maintenance or function. 
(a) White blood cell counts in LysM-cre; Mettl3fl/fl mice (n=6 for control, n=6 for LysM-cre; 
Mettl3fl/fl). 
(b) Frequencies of differential white blood cell counts in LysM-cre; Mettl3fl/fl mice (n=6 for control, 
n=6 for LysM-cre; Mettl3fl/fl).  
(c) Bone marrow cellularity (n=5 for control, n=5 for LysM-cre; Mettl3fl/fl). 
(d) Frequencies of bone marrow (left) and spleen (right) neutrophils (Mac1+Gr1+) and 
macrophages (Mac1+F4/80+) by flow cytometry (n=5 for control, n=5 for LysM-cre; Mettl3fl/fl). 
(e) qPCR analysis of cytokine expression by unstimulated and LPS-stimulated bone marrow 
macrophages (n=3 for control, n=3 for LysM-cre; Mettl3fl/fl). 
(f) Representative histogram (left) and quantification (right) of bone marrow macrophage 
phagocytosis of fluorescent-labeled beads (n=3 for control, n=3 for LysM-cre; Mettl3fl/fl). Shaded 
area denotes background staining (4oC incubation). 
All samples were from biologically independent animals. Values are shown as individual points 
with mean ± s.d. P values were determined by unpaired two-sided Student’s t-test. 
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Identification of m6A targets in HSCs 
To identify direct m6A targets in rare HSCs, we developed an m6A-tagged mRNA 
immunoprecipitation sequencing (meRIP-seq) method to analyze the m6A methylome of 2,000 
freshly sorted wild-type HSCs from 6-8 week old mice (Figure 2.9a-b). 2,073 transcripts 
(FDR<0.05 and fold>2) were significantly enriched in the m6A antibody-bound fraction compared 
to the non-bound fraction and were defined as high-confidence m6A targets (Figure 2.9c-d). 
This represented only ~9% of the genes expressed in the input mRNA fraction, suggesting that 
m6A preferentially marks a subset of genes in HSCs. We also performed meRIP-seq on Mettl3-
deficient HSCs from Mx1-cre; Mettl3fl/fl mice 10 days after pIpC administration. The enrichment 
of 995 transcripts (~48% of the high-confidence m6A targets) was significantly reduced (p<0.05) 
in Mettl3-deficient HSCs, suggesting that the m6A modification of these targets depended 
acutely on METTL3 (Figure 2.9e-f, Appendix B). The lack of complete elimination of m6A may 
be due to residue METTL3 protein, slow turnover of some target mRNAs or antibody detection 
of cap region m6Am, which unlike m6A, is known not to be regulated by Mettl3 but is also 
detected by the anti-m6A antibodies used (Mauer et al., 2017). 
Gene ontology (GO) analysis of m6A-tagged mRNAs demonstrated enrichment of genes 
related to nucleic acid metabolism, cell cycle regulation, transcription, RNA binding, and cellular 
stress responses, immune system development and hematopoiesis (Figure 2.10a). Supporting 
feed-forward regulation, several genes encoding components of the m6A pathway, including 
WTAP and m6A-reader proteins (reviewed in Meyer and Jaffrey, 2017), were also targets of m6A 
(Figure 2.10b). Consistent with the differentiation defects observed in Mettl3-deficient HSCs 
(Figures 2.1-2.8), we observed significant enrichment of genes associated with hematopoietic 
differentiation (Figure 2.10a). These data suggest that m6A regulates HSC differentiation by 
directly targeting hematopoietic differentiation pathways. Several known HSC regulators were 
identified as major targets of m6A, including Myc, Junb, and Tet2 (Figure 2.10c). More 
importantly, the enrichment of these genes in the m6A-bound fraction was significantly 
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decreased when Mettl3 was deleted from HSCs, suggesting the m6A modification of these 




Figure 2.9 meRIP-seq analysis identifies direct mRNA targets of m6A in HSCs. 
(a) Schematic of meRIP-seq workflow for low numbers of cells (such as HSCs).  
(b) Representative bioanalyzer graphs of meRIP-seq elution sample libraries after tagmentation 
generated using anti-m6A-antibody and IgG for immunoprecipitation. Experiment was repeated 
three times with similar results.  
(c) Heat map of transcript abundance between input, m6A-tagged, and unbound fractions. A 
total of 5,676 genes with log2(RPKM) ≥5 in ≥4 samples and stdev[log2(RPKM)]≥0.6 are shown. 
(d) Volcano plot of meRIP-seq transcript expression differences between m6A-tagged and 
unbound fractions in HSCs. The x-axis specifies the log2 fold-changes (FC) and the y-axis 
specifies the log10 false discovery rate (FDR). Dashed vertical and horizontal lines indicate 
the filtering criteria (log2(FC)>1 and FDR<0.05). Orange dots represent 2,621 transcripts 
showing statistically significant differences between bound and non-bound factions, of which 
2,073 are significantly enriched in the m6A-tagged fraction.  
(e) Volcano plot of meRIP-seq transcript expression differences between m6A-tagged and 
unbound fractions in Mx1-cre; Mettl3fl/fl (Mettl3Δ/Δ) HSCs 10 days after Cre induction. The x-axis 
specifies the log2 fold-changes (FC) and the y-axis specifies the log10 false discovery rate 
(FDR). Dashed vertical and horizontal lines indicate the filtering criteria (log2(FC)>1 or <-1 
and FDR<0.05). Orange dots represent transcripts showing statistically significant 
differences between m6A-tagged and un-bound factions, with select genes labeled. Data 
were from three biologically independent animals. The statistics was controlled for multiple 
testing by false discovery rate.  
(f) Comparison of m6A enrichment in wild-type (WT) HSCs vs Mettl3Δ/Δ HSCs. The x-axis 
specifies the log2 fold-change (FC) expression difference between m6A-tagged and unbound 
fractions in WT HSCs. The y-axis specifies the log2FC expression difference between m6A-
tagged and unbound fractions in Mx1-cre; Mettl3fl/fl (Mettl3Δ/Δ) HSCs 10 days after Cre induction. 
In both axes, positive sums represent enrichment in the m6A fraction. All dots shown are 
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transcripts found to be methylated in WT HSCs (log2(FC)>1 and FDR<0.05). Blue dots and 
select labeled genes represent transcripts found to have significantly different m6A 
enrichment in WT vs. Mettl3Δ/Δ (p<0.05). The dotted line represents equal m6A enrichment in 
WT vs. Mettl3Δ/Δ - dots below this line have decreased m6A enrichment in Mettl3Δ/Δ compared to 
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Figure 2.10 Identification of HSC regulators as m6A methylation targets. 
(a) Gene ontology analysis of biological processes enriched in m6A-tagged transcripts in WT 
HSCs. 
(b) meRIP-seq data showing that many components of the m6A pathway are targets of m6A in 
HSCs and this methylation is largely eliminated in Mx1-cre; Mettl3fl/fl (Mettl3Δ/Δ) HSCs 10 days 
after Cre induction. Data were from n=3 biologically independent samples for control and 
Mettl3Δ/Δ. 
(c) meRIP-seq data showing that transcripts of some known HSC regulators are m6A-tagged in 
wild-type HSCs, and this methylation is largely eliminated in Mx1-cre; Mettl3fl/fl (Mettl3Δ/Δ) HSCs 
10 days after Cre induction. Data were from n=3 biologically independent samples for control 
and Mettl3Δ/Δ.  
(d) Gene set enrichment analysis plots showing that Mettl3-deficient HSCs lose HSC gene 
signature, as determined by RNA-seq profiling. Analysis completed on gene list ranked by log10 
FDR and fold change sign, with enrichment determined after 1,000 permutations. Data were 
from n=3 biologically independent samples for control and Mettl3Δ/Δ. The statistics was 
computed using GSEA, and controlled for multiple comparisons by false discovery rate. 
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Deletion of Mettl3 leads to a loss of HSC identity without drastic alterations of the 
transcriptome 
To further understand the molecular mechanisms underpinning the functional defects of 
Mettl3-deficient HSCs, we performed RNA-seq analysis on Mettl3-deficient HSCs using Smart-
seq2 (Picelli et al., 2014). 830 genes showed significant expression differences (p<0.05). After 
stringent analysis with multiple comparisons correction, only 7 genes showed significant 
expression differences (FDR<0.05) between Mettl3-deficient and control HSCs (Figure 2.11a). 
As expected, Mettl3 was one of the most significantly down-regulated genes in Mettl3-deficient 
HSCs (Figure 2.11a). Gene set enrichment analysis (GSEA) (Subramanian et al., 2005) 
showed that Mettl3 deficiency predominantly led to a loss of expression of HSC identity-
associated genes defined by previous publications (Forsberg et al., 2010; He et al., 2011; 
Ivanova et al., 2002) (Figure 2.10d). These data suggest that METTL3-mediated m6A modestly 
altered HSC identity without profoundly impacting global mRNA levels.  
m6A has been shown to negatively regulate target mRNA stability (reviewed in Meyer 
and Jaffrey, 2014). We thus assessed whether m6A targets were up-regulated in Mettl3-deficient 
HSCs. 95 out of 384 up-regulated genes in Mettl3-defieient HSCs (p<0.05 and fold>1.2) were 
m6A targets (Figure 2.11b). But none of the 7 high-confidence differentially expressed genes 
(FDR<0.05) (Figure 2.11a) were high-confidence m6A targets. Compared to non-m6A targets, 
transcripts of m6A targets had slightly increased abundance in Mettl3-deficient HSCs (Figure 
2.11c).  Taken together, these data suggest that although m6A may directly control the transcript 




Figure 2.11 Loss of Mettl3 in HSCs does not cause major transcriptomic changes. 
(a) List of differentially expressed genes in control and Mx1-cre; Mettl3fl/fl HSCs 10 days after 
Cre induction by RNA-seq analysis (FDR<0.05). The statistics was controlled for multiple 
testing by false discovery rate. 
(b) Diagram of overlap between 384 up-regulated genes in Mettl3-deficient HSCs compared 
with controls (defined as p<0.05, fold>1.2) identified by RNA-seq and 2,073 methylated targets 
identified by meRIP-seq in wild-type HSCs. P value for enrichment was determined by 
hypergeometric probability test. 
(c) Cumulative distribution of log2 (gene expression ratios, Mettl3-deficient/control). Genes were 
separated as m6A and non-m6A as assessed by meRIP-seq. Insert is the box plot of the log2 
fold change in expression of non-m6A and m6A targets in HSCs. Plot displays the mean, 
standard deviation and interquartile range. P value was determined by two-sided Kolmogorov-
Smirnov test. 
(d) meRIP-qPCR data showing Myc enrichment in m6A-bound fraction in control and Mx1-cre; 
Mettl3fl/fl HSCs 10 days after pIpC treatment (n=3 for control, n=4 for Mx1-cre; Mettl3fl/fl). Data 
shown were normalized to the expression of Rplp0, a target found not to be methylated in HSCs 
by our meRIP-Seq analysis.  
(e) qPCR analysis of Myc expression by control and Mettl3-deficient HSCs 10-14 days after 
pIpC treatment (n=5 for control, n=6 for Mx1-cre; Mettl3fl/fl) and after overnight cytokine 
activation (right; n=5 for control, n=5 for Mx1-cre; Mettl3fl/fl). All samples were from biologically 
independent animals. Values are shown as mean ± s.d. P values were determined by paired 
two-sided Student’s t-test. 
(f) Gene set enrichment analysis plots, as determined by HSC RNA-seq profiling of control and 
Mx1-cre; Mettl3fl/fl HSCs 10 days after pIpC treatment (n=3 for control and Mettl3Δ/Δ). Mettl3-
deficient HSCs significantly lose Myc target genes. Analyses were completed on gene list 
ranked by log10 FDR and fold-change sign. P values were determined by the GSEA algorithm 
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after 1,000 permutations. The statistics was computed using GSEA, and controlled for multiple 





Vps33a      2.477 0.005
Mettl3 -2.374 0.014
Alox5     8.744 0.014
Crybb1 -10.367 0.030
Selp     1.786 0.030
Rnf32 -10.315 0.030
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Myc is a direct target of m6A in HSCs 
It has been shown that the MYC protein level is very low in HSCs, and is up-regulated 
upon differentiation through post-transcriptional mechanisms (Reavie et al., 2010; Ehninger et 
al., 2014). Furthermore, deletion of Myc blocks HSC differentiation while accumulated higher 
levels of MYC protein promotes HSC differentiation (Reavie et al., 2010; Wilson et al., 2004). 
Prompted by the observations that Myc is a major determinant of HSC differentiation and the 
phenotypic similarity between Myc and Mettl3 conditional knockout mice (accumulation of HSCs 
and blockage of differentiation), we investigated whether Myc is a direct target of m6A in HSCs. 
Our meRIP-seq analyses revealed that Myc was one of the top candidates highly enriched in 
m6A antibody-bound fraction compared with non-bound fraction (~30 fold enrichment; 
FDR=3.96x10-15) (Figure 2.9d and Figure 2.10c), in a Mettl3-dependent manner (Figure 2.9e-f 
and Figure 2.10c). We confirmed these meRIP-seq data using qPCR on independent samples 
(Figure 2.11d). Interestingly, Myc transcript levels were not significantly changed in Mettl3-
deficient HSCs compared with controls (Figure 2.11e). Using several previously published Myc 
target gene sets (Zeller et al., 2003; Liberzon et al., 2011), GSEA revealed a significant 
decrease in Myc target gene signatures in Mettl3-deficient HSCs (Figure 2.11f), suggesting that 
m6A may primarily regulate Myc mRNA translation.  
The Myc protein level can be directly measured by a knockin Myc-GFP translational 
reporter in vivo, where GFP is directly fused with MYC (Huang et al., 2008). To assess the 
impact of Mettl3 deletion on the level of Myc protein in HSCs, we generated Mx1-cre; Mettl3fl/fl; 
Myc-GFP mice. Consistent with prior publications (Reavie et al., 2010; Ehninger et al., 2014), 
HSCs express lower levels of MYC-GFP compared to hematopoietic progenitors at steady state 
(Figure 2.12a). Deletion of Mettl3 led to a modest significant reduction of MYC-GFP in HSCs 
(Figure 2.12b). Remarkably, upon activation to differentiate, Mettl3-deficient HSCs failed to up-
regulate MYC-GFP while control HSCs could readily do so (Figure 2.12b). Mettl3 deletion did 
not lead to changes in HSC Myc transcript levels under the activation condition (Figure 2.11e). 
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Given that m6A primarily regulates target mRNA stability and translation (Meyer and Jaffrey, 
2017; Yue et al., 2015), these data suggest that m6A is required for Myc mRNA translation in 




Figure 2.12 Mettl3 regulates HSC function by targeting Myc. 
(a) Quantification of the mean fluorescence intensity (MFI) of GFP expression in LSK subsets 
from Mx1-cre; Mettl3fl/fl; Myc-GFP mice or Myc-GFP controls at least 10 days after pIpC 
treatment (n=4 for Myc-GFP controls, n=4 for Mx1-cre; Mettl3fl/fl; Myc-GFP). Values were 
normalized to GFP-negative control cells of the same population.  
(b) Schematic of experimental design (top). Representative FACS plots of MYC-GFP 
expression in HSCs at steady-state (bottom left) and after cytokine activation (bottom right). 
Quantification of the mean fluorescence intensity (MFI) of GFP expression in HSCs after 
cytokine activation (n=7 for MYC-GFP controls, n=7 for Mx1-cre; Mettl3fl/fl; MYC-GFP). Values 
were normalized to GFP-negative control cells.  
(c) Schematic of experimental design (top). Representative FACS plots (bottom left) showing 
gating strategy for analysis of virally transduced colony cells derived from sorted HSCs from Mx1-
cre; Mettl3fl/fl mice 10 days after pIpC treatment. Representative FACS plot (middle) and 
quantification (right) of the frequency of Mac-1+ cells in virally transduced colonies from sorted 
HSCs from Mx1-cre; Mettl3fl/fl mice 10 days after pIpC treatment (n=3 for pMIG, n=3 for pMIG-
Myc). 
All samples were from biologically independent animals. Values are shown as individual points 







































































































































































Forced expression of MYC can rescue Mettl3-depleted HSC differentiation defects 
We tested whether forced expression of Myc can rescue the HSC differentiation defects 
caused by Mettl3 deletion. We transduced Mettl3-defiecent HSCs with Myc-expressing or 
control retrovirus (Figure 2.12c) and assessed their differentiation potential in vitro. Forced 
expression of Myc significantly rescued the differentiation defect of Mettl3-deficient HSCs 
compared with controls (Figure 2.12c). To assess whether Myc expression rescues HSC 
differentiation defects in vivo, we generated Mx1-cre; Mettl3fl/fl; Rosa-loxpMyc mice. The Rosa-
loxpMyc mice express Myc in a Cre-dependent manner (Calado et al., 2012), allowing testing of 
the impact of Myc expression on Mettl3-deficient HSCs in vivo. We treated 6-8 weeks old Mx1-
cre; Mettl3fl/fl; Rosa-loxpMyc and control Mx1-cre; Mettl3fl/fl mice with pIpC. However, Mx1-cre is 
known to be expressed in hepatocytes and consistent with previous reports of hepatocellular 
carcinoma development from liver Myc overexpression (Zheng et al., 2017), many Mx1-cre; 
Mettl3fl/fl; Rosa-loxpMyc mice developed liver nodules resembling hepatocellular carcinomas 
after the pIpC administration (Figure 2.13a). Analysis up to 3 weeks after pIpC treatment 
revealed normal blood counts in Mx1-cre; Mettl3fl/fl; Rosa-loxpMyc mice compared with control 
mice (Figure 2.13b), suggesting that the defects in the megakaryocyte lineage of Mettl3 
deletion are largely rescued by Myc expression. However, HSC frequency remained elevated in 
these mice compared to controls (Figure 2.13c), suggesting that the increase in HSC frequency 
may be related to perturbation of other m6A targets in addition to Myc. To specifically assess the 
function of HSCs, we transplanted 50 HSCs from the bone marrow of Mx1-cre; Mettl3fl/fl; Rosa-
loxpMyc, Mx1-cre; Mettl3fl/fl, and littermate control mice with competitor bone marrow cells. No 
reconstitution could be observed by HSCs from Mx1-cre; Mettl3fl/fl mice (Figure 2.13d-e), 
consistent with our prior results (Figure 2.6b). In contrast, 6 out of 12 mice transplanted with 
HSCs from Mx1-cre; Mettl3fl/fl; Rosa-loxpMyc mice were multi-lineage reconstituted four weeks 
after transplantation (Figure 2.13d-e). The recipients of Mx1-cre; Mettl3fl/fl; Rosa-loxpMyc HSCs 
with the highest chimerism died prior to subsequent analysis time points, likely due to 
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hematopoietic disease. However, all together these data suggest that forced expression of Myc 
can partially rescue HSC differentiation defects, both in vitro and in vivo and confirm that Myc is 




Figure 2.13 Forced Myc expression partially rescues Mettl3-depleted HSC differentiation 
defects in vivo.  
(a) Representative images of control and Mx1-cre; Mettl3fl/fl; Rosa-loxpMyc (Mx1/Mettl3/Myc) 
livers 3 weeks after pIpC treatment.  
(b) White blood cell counts, red blood cell counts and platelet counts in control and Mx1-cre; 
Mettl3fl/fl; Rosa-loxpMyc mice, as indicated (n=4 for control, n=4 for Mx1-cre; Mettl3fl/fl; Rosa-
loxpMyc). 
(c) Frequencies of hematopoietic stem cells in control and Mx1-cre; Mettl3fl/fl; Rosa-loxpMyc 
bone marrow (n=4 for control, n=4 for Mx1-cre; Mettl3fl/fl; Rosa-loxpMyc). 
(d) Frequencies of donor-derived CD45+, Mac1+, B220+, or CD3+ cells as indicated in control, 
Mx1-cre; Mettl3fl/fl and Mx1-cre; Mettl3fl/fl; Rosa-loxpMyc HSC recipients 4 weeks after 
transplantation (n=11 for control, n=4 for Mx1-cre; Mettl3fl/fl; n=12 for Mx1-cre; Mettl3fl/fl; Rosa-
loxpMyc). 
(e) Numbers of total recipients and responders after transplantation of 50 HSCs from control, 
Mx1-cre; Mettl3fl/fl or Mx1-cre; Mettl3fl/fl; Rosa-loxpMyc donors as indicated with 300,000 
competitor bone marrow cells. Recipients were judged as responders if they showed donor-
derived myeloid, B and T cells in the peripheral blood 4 weeks after transplantation. Samples 
were from independent recipients of two independent donor pairs from two experiments. P value 



























































































































































































































































We demonstrate that m6A is preferentially required for adult HSC differentiation in vivo 
and in vitro, but not mature myeloid cell maintenance or function. These results demonstrate 
that m6A is not a general cellular house-keeping mechanism, but rather a modification with 
specific roles in HSCs. Our results are in contrast to reports that show m6A inhibits 
differentiation of CD34+ human hematopoietic progenitor cells in vitro (Vu et al., 2017; Weng et 
al., 2017). Since those experiments were performed using shRNAs on cells of mixed 
populations of HSCs and progenitors in vitro, it is not clear what the effects on human HSCs are 
in vivo. Of note, we observed differences between HSCs and progenitors in their response to 
Mettl3 deletion (Figure 2.4 and Figure 2.5), suggesting that the roles of m6A in HSCs and 
progenitors need to be assessed independently. Consistent with our data, two other recent 
publications also showed that conditional deletion of Mettl3 led to accumulation of HSCs in the 
bone marrow (Yeo et al., 2018; Cheng et al., 2019).  Cheng et al similarly demonstrated that 
loss of Mettl3 reduces MYC expression and forced MYC expression can partially rescue HSC 
differentiation defects, consistent with our findings (Cheng et al., 2019).  
In contrast to its role in enabling HSC differentiation, m6A inhibits differentiation in AML 
leukemic cells (Vu et al., 2017; Weng et al., 2017; Barbieri et al., 2017).  This surprising 
difference may reflect distinct mechanisms of action for m6A in leukemic cells and HSCs, and 
suggests that it may be possible to develop m6A-targeted therapies against leukemia cells 
without damaging HSC function. More work is needed to elucidate the differences in the role of 
m6A between leukemic cells and HSCs. 
We found that HSC self-renewal and quiescence is largely intact after Mettl3 deletion 
(Figure 2.1a and Figure 2.6d). Thus, it appears that m6A specifically regulates HSC 
differentiation. m6A-mediated epitranscriptional regulation in HSCs may provide a fast and 
flexible mechanism to control mature blood cell output, allowing the organism to adapt to ever-
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changing physiological demands. Mettl3-deficient HSCs failed to establish bone marrow 
chimera in transplantation (Figure 2.7a-d), suggesting that m6A may regulate HSC homing 
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The Requirement for Mettl3-dependent m6A mRNA Methylation in the 





Hematopoietic stem cells (HSCs) reside in a bone marrow niche that supports them 
throughout life. Mesenchymal stromal cells (MSCs) are known to be a key component of the 
bone marrow niche, but how the niche and its HSC-supporting function are regulated is not fully 
understood. N6-methyladenosine (m6A) mRNA methylation has emerged as an important mode 
of epitranscriptional gene expression regulation affecting many biological processes. We show 
that deleting the m6A methyltransferase, Mettl3, from embryonic Prx1+ MSCs in the bone 
marrow niche of long bones causes a loss of normal bone marrow architecture and decreased 
bone marrow cellularity. Within the Mettl3-deficient bone marrow, HSCs were preferentially 
depleted, likely caused by the loss of a key HSC-supporting factor CXCL12 from the niche. 
Interestingly, deleting Mettl3 from post-natal MSCs using Lepr-cre did not impact HSC numbers, 
suggesting the dependence on Mettl3 is specific to the establishment of the niche, rather than 
its maintenance. Thus, our results revealed a key role for m6A in the establishment of the bone 




Throughout life, hematopoietic stem cells (HSCs) are supported by their local tissue 
microenvironment, or niche. During embryonic development, HSCs mainly form within the aorta-
gonad-mesonephros region before migrating to the fetal liver. Around birth, HSCs move to the 
bone marrow, where they remain throughout life. Normal hematopoiesis requires a functional 
HSC-supporting niche in the bone marrow. The bone marrow niche is composed of many cell 
types, one of the most important of which is perivascular mesenchymal stromal cells (MSCs) 
(reviewed in Lee et al., 2017). MSCs, often identified by their expression of paired related 
homeobox 1 (Prx1) or leptin receptor (Lepr), have been shown to be adjacent to HSCs and 
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secrete key HSC-supporting cytokines stem cell factor (Scf) and CXCL12 (also known as 
stromal cell-derived factor 1 or Sdf-1) (reviewed in Lee et al., 2017). Prx1 is expressed 
throughout mesenchymal cells of the developing limb bud from E9.5 (Logan et al., 2019). 
Lineage tracing of Prx1+ cells revealed labeling of chondrocytes, osteoblasts, adipocytes, and 
stromal cells, demonstrating that Prx1 expression occurs in early multipotent mesenchymal 
progenitors (Kawanami et al., 2009; Sanchez-Gurmaches et al., 2015). Transplantation of 
developing progenitor MSCs at E14.5 into recipient kidney capsules results in the formation of 
ectopic bone marrow with recipient HSCs, demonstrating that these cells are capable of 
generating all necessary mesenchymal components of the HSC niche (Chan et al., 2009).  In 
contrast, Lepr is expressed in post-natal Prx1+ MSCs in the bone marrow, suggesting they are 
derived from and downstream of Prx1+ mesenchymal progenitors (Zhou et al., 2014). It is not 
understood how HSC-supporting MSCs are generated and maintained throughout life. Despite 
attempts to create in vitro HSC-supporting environments, current technology is limited and 
unable to replicate the full capacity of the bone marrow niche. Understanding how the niche is 
formed and regulated is important for developing such technologies and offers great potential 
medical benefit in advancing HSC-based therapies. 
We have previously shown that the epitranscriptional modification N6-methyladenosine 
(m6A) and its methyltransferase METTL3 play important roles in HSC-intrinsic regulation (Lee et 
al., 2019), but it was unknown whether m6A and METTL3 also impact HSC-extrinsic regulation. 




Prx1-cre; Mettl3fl/fl mice have reduced survival and abnormal limb development  
To assess if Mettl3 plays a role in regulating mesenchymal stromal cells, the key 
component of the HSC niche in the bone marrow, we crossed Prx1-cre (Logan et al., 2002) with 
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Mettl3fl (Lee et al., 2019; described in Chapter 2) to generate Prx1-cre; Mettl3fl/fl mice. As Prx1-
cre starts to recombine in the limb at E9.5 (Logan et al., 2002), this allows us to delete Mettl3 
from limb bone marrow environment prior to the establishment of hematopoiesis around E17.5 
(Christensen et al., 2004). Prx1-cre; Mettl3fl/fl mice were born in lower than expected numbers 
based on Mendelian ratios (Figure 3.1a) and displayed significantly decreased survival 
compared to littermate controls postnatally (Figure 3.1b). Prx1-cre; Mettl3fl/fl mice have similar 
body size to controls at birth, but are much smaller at later stages of development (Figure 3.1c), 
suggesting stunted growth. Prx1-cre; Mettl3fl/fl mice also have much shorter forelimb and 
hindlimbs and smaller and paler long bones (Figure 3.1c). Consistent with their paler 
appearance, hematoxylin and eosin staining of the bones revealed decreased hematopoietic 
cells and an abundance of eosin-stained mesenchymal tissue in Mettl3-depleted limbs (Figure 
3.1d). By P14, Prx1-cre; Mettl3fl/fl femurs are almost completely filled with eosin-stained 
mesenchymal tissue and have no central bone marrow cavity (Figure 3.1d).  These data 




Figure 3.1 Prx1-cre; Mettl3fl/fl mice have reduced survival and abnormal limb 
development.  
(a) Observed numbers of Prx1-cre; Mettl3fl/fl and control mice out of 150 pups alive at P0 
compared to expected numbers based on Mendelian ratios. P-valued based on two-tailed 
binomial test.  
(b) Kaplan-Meyer survival analysis of control and Prx1-cre; Mettl3fl/fl mice. P value by log-rank 
test (n=99 for control, n=16 for Prx1-cre; Mettl3fl/fl). 
(c) Representative images of Prx1-cre; Mettl3fl/fl and control mice above corresponding images 
of femurs and tibias. Mice are aged P0, P5, P15, as indicated. Arrows point to visibly abnormal 
Prx1-cre; Mettl3fl/fl forelimbs.  
(d) Representative images of hematoxylin and eosin staining from Prx1-cre; Mettl3fl/fl and control 
femurs at P0 or P14, as indicated. Black boxes indicate areas shown in higher magnification to 
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Prx1-cre; Mettl3fl/fl mice have perturbed hematopoiesis and a reduction in bone marrow 
HSCs 
To specifically assess how their abnormal long bone development affected 
hematopoiesis, we analyzed the bone marrow from Prx1-cre; Mettl3fl/fl hindlimbs from birth to 
two weeks of age. Mettl3-deficient bones had reduced bone marrow cellularity at all stages 
examined (Figure 3.2a), consistent with histologic examination (Figure 3.1d). By flow 
cytometry, we found a reduction in the frequency of B220+ B cells, but no differences in the 
frequency of other types of mature blood cells analyzed, including CD41+ megakaryocytes, 
Mac1+Gr1+ myeloid cells, Ter119+ red blood cells and CD3+ T cells.  (Figure 3.2b). However, 
the frequency of Lin-Sca1+cKit+ (LSK) hematopoietic progenitors also trended towards a 
reduction at all stages (Figure 3.2c-d), with the most dramatic reduction observed in the 
CD150+CD48-LSK HSC compartment (Figure 3.2e). By two weeks of age, Prx1-cre; Mettl3fl/fl 
hindlimbs contained an average 160-fold fewer HSCs compared to littermate controls (Figure 
3.2f), with nearly no HSCs. In contrast, Prx1-cre; Mettl3fl/fl vertebral marrow displayed normal 
HSC frequency (Figure 3.2g), consistent with the pattern of Prx1-cre expression in the limbs, 
but not the axial bones (Logan et al., 2002). These data suggest that a loss of Mettl3 from 
MSCs prevents normal hematopoiesis with a profound impact on HSCs.  
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Figure 3.2 Prx1-cre; Mettl3fl/fl mice have perturbed hematopoiesis and a reduction in bone 
marrow HSCs. 
(a) Bone marrow cellularity per hindlimb (n=3 for control (P0), n=3 for Prx1-cre; Mettl3fl/fl (P0), 
n=3 for control (P5), n=3 for Prx1-cre; Mettl3fl/fl (P5), n=3 for control (P10), n=3 for Prx1-cre; 
Mettl3fl/fl (P10), n=7 for control (P14-16), n=7 for Prx1-cre; Mettl3fl/fl (P14-16)). 
(b) Frequencies of indicated bone marrow cell populations from P14-P16 hindlimbs (n=3 for 
control, n=3 for Prx1-cre; Mettl3fl/fl). 
(c) Representative flow cytometry gating strategy for HSCs in P14-P16 hindlimb bone marrow. 
Percentages reflect the frequency of the indicated population out of live bone marrow cells.  
(d) Frequencies of bone marrow Lin-Sca-1+c-Kit+ (LSK) progenitors (n=3 for control (P0), n=3 for 
Prx1-cre; Mettl3fl/fl (P0), n=4 for control (P5), n=4 for Prx1-cre; Mettl3fl/fl (P5), n=3 for control 
(P10), n=3 for Prx1-cre; Mettl3fl/fl (P10), n=3 for control (P14-16), n=3 for Prx1-cre; Mettl3fl/fl 
(P14-16)). 
(e) Frequency of bone marrow HSCs (n=3 for control (P0), n=3 for Prx1-cre; Mettl3fl/fl (P0), n=4 
for control (P5), n=4 for Prx1-cre; Mettl3fl/fl (P5), n=3 for control (P10), n=3 for Prx1-cre; Mettl3fl/fl 
(P10), n=3 for control (P14-16), n=3 for Prx1-cre; Mettl3fl/fl (P14-16)). 
(f) Bone marrow HSCs per hindlimb (n=3 for control (P0), n=3 for Prx1-cre; Mettl3fl/fl (P0), n=3 
for control (P5), n=3 for Prx1-cre; Mettl3fl/fl (P5), n=3 for control (P10), n=3 for Prx1-cre; Mettl3fl/fl 
(P10), n=3 for control (P14-16), n=3 for Prx1-cre; Mettl3fl/fl (P14-16)). 
(g) Frequency of HSCs in the vertebral bone marrow at P14-16 (n=2 for control, n=3 for Prx1-
cre; Mettl3fl/fl). 
(h) Frequency of liver HSCs (n=3 for control (P0), n=3 for Prx1-cre; Mettl3fl/fl (P0), n=4 for 
control (P5), n=4 for Prx1-cre; Mettl3fl/fl (P5)). 
(i) Frequency of spleen HSCs (n=3 for control (P0), n=3 for Prx1-cre; Mettl3fl/fl (P0), n=4 for 
control (P5), n=4 for Prx1-cre; Mettl3fl/fl (P5), n=3 for control (P10), n=3 for Prx1-cre; Mettl3fl/fl 
























































































































































































































































































HSCs predominantly reside in the fetal liver during embryonic development and migrate 
to the bone marrow around birth (Christensen et al., 2004). Newborn Prx1-cre; Mettl3fl/fl mice 
had normal HSC numbers in the livers compared with controls, suggesting the observed HSC 
depletion phenotype in the bone marrow was not due to HSC defects in the fetal liver stage 
(Figure 3.2h). Interestingly, Prx1-cre; Mettl3fl/fl mice had more HSCs in the liver at P5 compared 
to controls (Figure 3.2h). Fetal liver HSCs appeared to have a normal capacity to migrate into 
the bone marrow, as the vertebrae of Prx1-cre; Mettl3fl/fl mice had normal HSCs frequencies 
(Figure 3.2g). The frequency of splenic HSCs is also unaffected by loss of Mettl3 in MSCs 
(Figure 3.2i), so the increase in liver HSCs is not likely to be explained by reactive 
extramedullary hematopoiesis. Thus, the loss of phenotypic HSCs observed in the bone marrow 
(Figure 3.2e-f) is likely due to a decreased migration of fetal liver HSCs into the Mettl3-depleted 
bone marrow environment.  
Prx1-cre; Mettl3fl/fl hindlimb bone marrow has reduced reconstitution potential 
To definitively determine if the number of functional HSCs in Prx1-cre; Mettl3fl/fl limbs is reduced, 
we performed limiting dilution transplantation assays. We transplanted differing doses of bone 
marrow cells (10,000, 30,000, or 80,000 cells) from control or Mettl3-depleted hindlimbs into 
irradiated recipient mice along with 300,000 recipient-type radioprotection bone marrow cells 
and measured the fraction of recipients that were successfully reconstituted in all major blood 
lineages (myeloid, B and T cells) at each dose, demonstrating HSC function. This allowed us to 
extrapolate the frequency of functional HSCs within the bone marrow and revealed a four-fold 
reduction in the frequency of functional HSCs within Mettl3-deficient bone marrow (Figure 
3.3c). Thus, Prx1-cre; Mettl3fl/fl limb bone marrow has reduced long-term multi-lineage 
reconstitution potential, demonstrating that Mettl3 in MSCs is required for normal HSC 
maintenance.  
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Figure 3.3 Prx1-cre; Mettl3fl/fl  hindlimb bone marrow has reduced HSC frequency and 
function.  
Limiting dilution transplantation of 10,000, 30,000, or 80,000 donor whole bone marrow cells as 
indicated from Prx1-cre; Mettl3fl/fl or Mettl3fl/fl controls with 300,000 competitor cells. Recipients 
were judged as responders if they showed donor-derived myeloid, B and T cells in the 
peripheral blood were assessed up to 16 weeks after transplantation. Samples were from 
independent recipients of two independent donor pairs from two experiments. Graph of results 
(left) and numbers of recipients and responders for the indicated conditions (right).  

























































CXCL12-expressing cells and CXCL12 expression is reduced in Prx1-cre; Mettl3fl/fl  
hindlimbs 
Our data (Figure 3.2-3.3) suggest that the HSC-supporting function of bone marrow 
MSCs is compromised after Mettl3 deletion. Cxcl12 is a chemokine known to be highly and 
specifically expressed by perivascular MSCs in adult bone marrow and has been shown to be 
required for HSC retention and maintenance and B cell development in the bone marrow 
(Greenbaum et al., 2013; Ding and Morrison, 2013; Tokoyoda et al., 2004). Previous genetic 
studies have shown that loss of Cxcl12 or its receptor, Cxcr4, impairs the establishment of bone 
marrow hematopoiesis with a loss of bone marrow cellularity, HSCs, and B cells (Nagasawa et 
al., 1996; Ma et al.,1998; Tokoyoda et al., 2004), suggesting METTL3 may regulate the niche 
function of MSCs through regulating CXCL12 expression. To directly test whether there are 
defects of Cxcl12 expression with bone marrow niche cells, we labeled HSC-supporting MSCs 
using the genetic transcriptional reporter Cxcl12DsRed knock-in mice (Ding and Morrison, 2013). 
Histologic sections of Prx1-cre; Mettl3fl/fl long bones showed that fewer Cxcl12-DsRed+ cells 
were in the bone marrow from P0 compared with controls (Figure 3.4a), around the time when 
HSCs would normally migrate from the fetal liver to the bone marrow (Christensen et al., 2004). 
By P14, control long bones contained abundant Cxcl12-DsRed+ stromal cells throughout the 
marrow cavity (Figure 3.4b). However, Prx1-cre; Mettl3fl/fl long bones contained significantly 
fewer Cxcl12-DsRed+ cells that are restricted to small areas of the marrow, rather than evenly 
distributed as in Cxcl12DsRed control mice (Figure 3.4b).  
To understand how loss of Mettl3 influences Prx1+ MSCs, we crossed the CAG-loxP-
stop-loxP-ZsG (ZsGfl) Cre reporter allele (Madisen et al., 2010) into the Prx1-cre; Mettl3fl/fl mice 
to trace the cell fate of Prx1+ MSCs. Sections of Prx1-cre; Mettl3fl/fl;ZsGfl/+; Cxcl12DsRed/+ 
hindlimbs revealed Cre expression in cells throughout the Mettl3-depleted bones (Figure 3.4b). 
However, while Prx1+-derived ZsG+ cells in the control marrow are largely Cxcl12-DsRed+ 
stromal cells, Mettl3-depleted mice have long bones filled with ZsG+ mesenchymal tissue that 
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does not express Cxcl12-DsRed (Figure 3.4b), suggesting a cell fate change of Mettl3-deficient 
MSCs.  
By flow cytometry, there was a significant reduction in the frequency of CD45-Ter119-
Cxcl12-DsRed+ cells in Mettl3-depleted long bones compared to littermate controls (Figure 
3.4c). Using PDGFRα, an alternative marker for MSCs (Morikawa et al., 2009), similar results 
were obtained (Figure 3.4d). As our Cxcl12DsRed allele is a transcriptional reporter (Ding and 
Morrison, 2013), the levels of DsRed were not a direct readout of CXCL12 protein. To assess 
CXCL12 protein expression within the MSCs, we performed intracellular flow cytometry using an 
anti-CXCL12 antibody (R&D IC350F). This revealed a notable decrease in the expression of 
CXCL12 in CD45-Ter119-PDGFRα+ stromal cells (Figure 3.4e). Thus, Prx1-cre; Mettl3fl/fl limb 
bones have not only contain fewer HSC-supporting stromal cells, but also express less CXCL12 
protein from those MSCs. Therefore, our data suggest that the hematopoietic defects observed 
in Prx1-cre; Mettl3fl/fl limbs are at least partially through the loss of CXCL12 from Prx1+ MSCs.  
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Figure 3.4 CXCL12-expressing cells and CXCL12 expression is reduced in Prx1-cre; 
Mettl3fl/fl  hindlimbs.  
(a) Representative confocal images of P0 Cxcl12-DsRed control and Prx1-cre; Mettl3fl/fl; 
Cxcl12DsRed/+ femurs. Nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI, blue). 
(b) Representative confocal images of P14 ZsGfl/+; Cxcl12DsRed/+ control and Prx1-cre; Mettl3fl/fl; 
ZsGfl/+; Cxcl12DsRed/+ femurs. Nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI, 
blue). 
(c) Representative flow cytometry plots (left) and quantification (right) of CD45-Ter119-Cxcl12-
DsRed+ cells in P14-P16 hindlimb bones. Percentages reflect the population frequency out of 
live bone marrow cells (n=3 for Cxcl12DsRed/+ control, n=2 for Prx1-cre; Mettl3fl/fl; Cxcl12DsRed/+). 
(d) Frequency of CD45-Ter119-PDGFRα+ stromal cells in P14-16 Prx1-cre; Mettl3fl/fl or control 
hindlimb bones (n=4 for control, n=3 for Prx1-cre; Mettl3fl/fl). 
(e) Representative flow cytometry plot (left) and quantification (right) of CXCL12-FITC mean 
fluorescence intensity (MFI) in all bone marrow cells or CD45-Ter119-PDGFRα+ cells in P14-
P16 hindlimbs, as indicated (n=4 for control, n=3 for Prx1-cre; Mettl3fl/fl). Values given are in 
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Lepr-cre; Mettl3fl/fl mice do not display hematopoietic defects   
In adult bone marrow, HSC-supporting MSCs can be identified by their expression of 
Leptin receptor (Lepr) or Prx1. However, while Prx1-cre is expressed during embryogenesis 
(Logan et al., 2002), Lepr-cre is expressed only after birth (Zhou et al., 2014). To determine if 
Mettl3 plays a role in regulating the post-natal bone marrow niche, we generated Lepr-cre; 
Mettl3fl/- mice. Consistent with prior reports (Zhou et al., 2015; Ding et al., 2012; Ding and 
Morrison, 2013), Lepr-cre efficiently deleted Mettl3 from CD45- Ter119- PDGFRα+ stromal cells 
(Figure 3.5a). Interestingly, CD45- Ter119- PDGFRα+ stromal cells express lower levels of 
Mettl3 compared to whole bone marrow (Figure 3.5a). At 6 to 8 weeks of age, Lepr-cre; Mettl3fl/- 
mice displayed normal white blood cell, red blood cell, or platelet counts compared to controls 
(Figure 3.5b). They also had normal bone marrow cellularity, HSC frequency, or CD45- Ter119- 
PDGFRα+ stromal cell frequency (Figure 3.5c-e). While more work is needed to fully 
characterize the hematopoietic system of Lepr-cre; Mettl3fl/- mice, our results thus far show that 
depletion of Mettl3 from adult Lepr+ MSCs does not result in the same severe HSC defects as 
loss of Mettl3 from embryonic Prx1+ MSCs. Thus, Mettl3 may have a preferential role in the 
establishment of the HSC niche, as opposed to its maintenance.  
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Figure 3.5 Lepr-cre; Mettl3fl/- mice do not display hematopoietic defects.  
(a) qPCR analysis of Mettl3 mRNA expression in control whole bone marrow and CD45-Ter119-
PDGFRα+ stromal cells from Lepr-cre; Mettl3fl/- or control mice (n=*** for control bone marrow, 
n=6 for control stromal cells, n=6 for Lepr-cre; Mettl3fl/- stromal cells). 
(b) White blood cell, red blood cell, and platelet counts as indicated in adult Lepr-cre; Mettl3fl/- or 
control mice (n=3 for control, n=3 for Lepr-cre; Mettl3fl/-). 
(c) Bone marrow cellularity per hindlimb in adult Lepr-cre; Mettl3fl/- or control mice (n=3 for 
control, n=3 for Lepr-cre; Mettl3fl/-). 
(d) Frequency of bone marrow HSCs in adult Lepr-cre; Mettl3fl/- or control mice (n=3 for control, 
n=3 for Lepr-cre; Mettl3fl/-). 
(e) Frequency of CD45-Ter119-PDGFRa+ stromal cells in adult Lepr-cre; Mettl3fl/- or control mice 
(n=3 for control, n=3 for Lepr-cre; Mettl3fl/-). 






























































































































































The results reported are preliminary and only broadly characterize the effects of loss of 
Mettl3 from long bone MSCs, a key component of the HSC niche. We have demonstrated that 
Mettl3 is required in developmental MSCs for the establishment of the bone marrow niche and 
normal hematopoiesis in the limbs. Loss of Mettl3 from Prx1+ cells results in decreased survival 
in utero and postnatally (Figure 3.1a-b). While we do not know the cause, we suspect their 
survival defect could be related to Prx1+ expression and Mettl3 deletion in embryonic cranial 
mesenchyme (Logan et al., 2002) and to their decreased size, which may confer a competitive 
disadvantage for maternal support. It is unlikely to be related to hematopoietic defects, as we 
found normal HSC frequencies in fetal livers and vertebral marrow (Figure 3.2g-h). In contrast, 
we saw a preferential loss of HSCs and B cells from Mettl3-deficient limb bone marrow (Figure 
3.2), at least partially caused by the loss of CXCL12-expressing MSCs (Figure 3.4). As HSCs 
remain longer in Prx1-cre; Mettl3fl/fl livers (Figure 3.2g), we hypothesize that these mice have 
defects in HSC migration to the long bones from their loss of CXCL12-expressing MSCs. As it 
appears that fetal liver HSCs can be maintained in the vertebral marrow normally (Figure 3.2g), 
the impairment of HSC-supporting activity seems specific to the Mettl3-deficient bone marrow. 
Interestingly, Wu et al. demonstrated that the key HSC-regulating cytokines Cxcl12 and Scf are 
m6A targets in adult MSCs in vitro (Wu et al., 2018). While m6A targets may be context and cell-
type dependent, it is very possible that Cxcl12 and Scf are also m6A targets of developing MSCs 
in vivo. We are performing m6A methylome sequencing to directly address whether Cxcl12 and 
Scf are targets of m6A in Prx1+ MSCs in fetal long bones. Thus, we hypothesize that loss of 
Mettl3 perturbs m6A regulation of Cxcl12 and Scf, causes loss of CXCL12 (and possibly SCF 
and other niche factors) expression and compromises HSC-supporting function. Further work is 
ongoing to explore this hypothesis.  
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A recent study found that Mettl3 deletion in MSCs leads to osteoporosis in adult mice, 
shifting the balance of MSC fate towards adipogenesis, rather than bone formation (Wu et al., 
2018). Our work is consistent with this notion of m6A regulation of MSC fate, as we have found 
Mettl3 to be critical for MSC development of normal limb mesenchymal tissue, including HSC-
supporting stromal cells, to the detriment of hematopoiesis. Interestingly, Lepr-cre; Mettl3fl/- mice 
do not display the same hematopoietic defects as Prx1-cre; Mettl3fl/fl mice. One possible 
explanation for this is residual expression of Mettl3 from Lepr+ cells from incomplete deletion 
(Figure 3.5e). However, our experience using Lepr-cre has shown over 90% efficiency in other 
conditional mouse models and strong phenotypic effects when used to conditionally delete 
important niche factors like Scf and Cxcl12 (Zhou et al., 2015; Ding et al., 2012; Ding and 
Morrison, 2013). It is possible that we are achieving lower deletion efficiencies due to 
contamination from other bone marrow cells, which express higher levels of Mettl3 than stromal 
cells and may cause us to underestimate the deletion efficiency (Figure 3.5a). Thus, another 
possibility is that there is a functional difference in the role of Mettl3 within MSCs at different 
developmental stages. This also raises the possibility of two distinct cell identities: 
developmental Prx1+ MSCs and their downstream Lepr+ MSCs progenies. Understanding the 
relationships between these different cell types offers great potential in furthering our 
understanding of how the HSC niche is formed and regulated.  
Consistent with our findings on the role of Mettl3 in HSCs and myeloid cells (Chapter 2), 
these results also suggest that Mettl3 has specific roles in stem and progenitor cells and is more 
dispensable in downstream cells. With roles for m6A also reported in embryonic stem cells and 
neural progenitors, it is possible that Mettl3 and m6A may be a distinguishing feature of stem 
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CONCLUSIONS AND GENERAL DISCUSSION 
 
Hematopoietic stem cells (HSCs) are a paradigm tissue stem cell, characterized by their 
ability for life-long self-renewal and multi-lineage differentiation. HSC function is regulated by 
complex cell-intrinsic and -extrinsic pathways, but the mechanisms that control balanced self-
renewal and differentiation are poorly understood. I have shown that the epitranscriptional 
modification N6-methyladenosine (m6A) plays critical roles in regulating HSC function, both 
within the HSC itself (Chapter 2, Figure 4.1a) and through regulation of HSC-supporting 
mesenchymal stromal cells (MSCs) in the bone marrow (Chapter 3, Figure 4.1b). While the role 
of DNA modifications in HSC function has been characterized (Broske et al., 2009; Challen et 
al., 2012), this is one of the first works to demonstrate the role for RNA modification in adult 
stem cells.  
HSCs seem to be preferentially affected by loss of Mettl3, while mature myeloid cells 
display no obvious defects (Chapter 2). This specific requirement for m6A in HSCs, but not more 
mature cells, may be one explanation for why previous studies on broader populations of 
hematopoietic cells, such as CD34+ HSPCs and lineage-negative cells, did not report significant 
effects from loss of Mettl3 (Barbieri et al., 2017; Vu et al., 2017). In contrast, I have 
demonstrated that focusing specifically on the HSC compartment reveals an HSC-specific 
reliance on m6A-regulation. To my knowledge, this is the first time that m6A has been shown to 
have differential importance at the stem cell level, but little importance in more mature cells, 
thus giving us greater insight into the unique properties of stem cells and how they are distinct 
from their progeny. 
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Around the time that these results described in Chapter 2 were published, several other 
studies on the role for m6A within HSCs were also released. They similarly found that loss of 
Mettl3 from adult HSCs causes an expansion of the HSC pool and reduced reconstitution 
potential from a defect in differentiation (Yao et al., 2018; Cheng et al., 2019).  Cheng et al. also 
found that Myc was a direct m6A target and the HSC differentiation defect could be partially 
rescued by Myc overexpression, confirming our findings (Chapter 2). Thus, we and several 
other investigators have found that m6A specifically regulates HSC differentiation over other 
aspects of HSC function. My preliminary work in MSCs also suggests a role for m6A in MSC fate 
determination (Chapter 3). These observations are consistent with findings in the broader m6A 
field, including studies on embryonic stem cell, neural progenitors, embryonic endothelium, 
naïve immune cells and leukemia stem cells, all suggesting that m6A has specific roles for the 
transition from an undifferentiated to more differentiated state.   
My work on m6A is also consistent with prior studies on HSC differentiation and offers 
some additional insights into past findings. MYC is a master regulator of HSC differentiation that 
is known to be post-translationally regulated by ubiquitin-mediated degradation (Reavie et al., 
2010; Wilson et al., 2004; Ehninger et al., 2014). My work and others demonstrates that 
expression of MYC protein, but not RNA, is also highly regulated by m6A, making m6A an 
additional post-transcriptional regulator of Myc and HSC differentiation (Chapter 2; Cheng et al., 
2019).  
This fits within the context of other proposed regulators of Myc, including RBM15. 
Rbm15 knock-out mice expanded LSK, HSC, myeloid and megakaryocyte populations with 
defects in HSC reconstitution capacity and B cell and megakaryocyte differentiation (Niu et al., 
2009; Raffel et al., 2007). Megakaryocyte differentiation defects could be partially rescued by 
Myc overexpression, so it was suggested that the hematopoietic abnormalities were related to 
regulation of Myc by RBM15 (Niu et al., 2009). However, the molecular mechanisms were never 
fully elucidated. At the time of these studies, RBM15 was not yet known to be involved in the 
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m6A methyltransferase complex, so whether the effects of loss of Rbm15 were due to impacts 
on the m6A pathway or a different function of Rbm15 was not clear. Mx1-cre; Mettl3fl/fl mice 
show striking similarities to Rbm15 knock-out mice in their expanded LSKs, HSCs, and 
megakaryocyte pools with abnormal differentiation (Chapter 2). Given the role of m6A in the 
regulation of Myc that I have demonstrated and the similarities in the Rbm15 knock-out 
phenotype, it seems probable that the effects of loss of Rbm15 are caused by disruption of the 
m6A pathway.  
As m6A has been shown to play important roles in leukemia cell fate, m6A and METTL3 
have been proposed to be promising therapeutic targets. However, my work and others’ has 
shown that loss of m6A also has dramatic effects on HSCs, and this will be an important 
consideration for development of these therapies (Yao et al., 2018; Cheng et al., 2019). 
Interestingly, the role of m6A in HSCs seems to be opposite the proposed role of m6A in 
leukemia cells.  Several groups have found that loss of m6A through depletion of Mettl3 or 
Mettl14 promotes differentiation of leukemia cells (Barbieri et al., 2017; Vu et al., 2017; Weng et 
al., 2017). However, despite having opposite effects on differentiation, m6A regulates Myc in 
both myeloid leukemia cells and HSCs (Barbieri et al., 2017; Vu et al., 2017; Weng et al., 2017; 
Yao et al., 2018; Cheng et al., 2019). What causes this difference in cellular fate between the 
cell types is unclear. The observed effects in leukemia cells were seen using leukemia cell lines 
in vitro and cultured leukemia cells transplanted into recipient mice (Barbieri et al., 2017; Vu et 
al., 2017; Weng et al., 2017), so it is possible that different findings may result when depleting 
m6A in other in vivo leukemia models, such as with genetic mouse models, which we are 
currently exploring. However, it is also possible that the observed effects differ from differing 
m6A targets and m6A reader proteins, which are known to be context dependent (Xiao et al., 
2019). Though I show that Myc is a major m6A target regulating HSC differentiation, we also 
identified 994 other Mettl3-dependent m6A targets within HSCs. Some of those targets include 
known HSC regulators like Tet2 and Junb, which have also been implicated in leukemogenesis 
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(Moran-Crusio et al., 2011; Li et al., 2011; Passague et al., 2001). How these targets are 
impacted after Mettl3-depletion and whether their dysregulation also impacts HSC function is 
still unknown. Furthermore, understanding how the full spectrum of m6A targets and readers 
differ between leukemia cells and HSCs also needs further study. All of these unknowns will be 
important to investigate for the development of any METTL3- or m6A-targeted therapies.  
Characterizing epitranscriptional regulation requires appropriate tools, which have only 
begun to be developed. The first methods to profile m6A targets have been heavily reliant on 
anti-m6A antibodies for immunostaining, immunoblotting and immunoprecipitation experiments 
(Meyer et al., 2012; Dominissini et al., 2012). Unfortunately, these antibodies are not specific to 
m6A; they also recognize another modified adenosine, N6,2’-O-dimethyladenosine (m6Am) 
(Mauer et al., 2017). m6Am is not methylated by METTL3 or recognized by m6A reader proteins 
(Mauer et al., 2017). This antibody cross-reactivity has only recently been appreciated, 
complicating interpretation of previous studies, including my own. While were able to show that 
48% of our high confidence m6A mRNA targets in HSCs were Mettl3-dependent, it is possible 
that some of the other high confidence targets contain m6Am, rather than m6A (Figure 2.9c-d). 
However, recent technical advances in m6A profiling have allowed for m6A and m6Am to be 
distinguished (Linder et al., 2015). Newer antibody-independent m6A profiling methods have 
also allowed for m6A-specific transcriptome characterization, and these results have suggested 
that antibody-based methods may be underestimating the true number of m6A modifications 
within a transcriptome (Garcia-Campos et al., 2019; Meyer, 2019). Thus, it is likely that there 
are additional m6A targets in HSCs that were not identified in my work, but may have important 
roles in m6A-based regulation of HSC function.  
The m6A profiling methods in my work were limited to the identification of m6A-containing 
transcripts within HSCs and MSCs, leaving valuable information unknown, such as the location 
and density of m6A sites on a transcript and the stoichiometry of m6A-modified targets within a 
transcriptome.  However, recent advances in m6A profiling could provide those additional 
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insights. Techniques such as “m6A individual-nucleotide resolution crosslinking and 
immunoprecipitation” (miCLIP) can determine the exact location and number of methylation 
sites on a given transcript (Linder et al., 2015). In certain contexts, it is now also possible to 
determine the stoichiometry of a given methylation site among a transcript pool (Garcia-Campos 
et al., 2019). More complete characterization of the methylation profiles could offer further 
explanation for current unknowns, such as how HSCs are distinguished from downstream 
progenitors which also express high levels of Mettl3 (Figure 2.1a).  
There is also emerging evidence that METTL3 has functions independent of its role as a 
methyltransferase. METTL3 has been localized to both the nucleus and cytoplasm, with differing 
hypothesized functions in the different subcellular compartments. When METTL3 is localized to 
nuclear speckles, it is found in association with other members of the m6A-methyltransferase 
complex and is thus assumed to function in the writing of m6A on pre-mRNA targets (Meyer and 
Jaffrey, 2017). However, in human cancer cell lines, cytoplasmic METTL3 has been shown to 
associate with ribosomes and form “loops” that promote ribosome retention on transcripts and 
increase translation efficiency, independent of METTL3’s catalytic activity (Lin et al., 2016). 
Determining which effects from loss of Mettl3 in HSCs and MSCs are due to m6A-perturbation 
versus m6A-independent METTL3 functions are critical for the development of effective m6A- or 
METTL3-based therapeutics.  
While the functional importance of m6A has only been recognized in the last decade, it is 
quickly emerging as a major subject of interest and has sparked the investigation of over 150 
other RNA modifications (Boccaletto et al., 2018). With ongoing development of new tools to 
study RNA modifications, it is likely that further work will answer remaining questions about HSC 
regulation by m6A and characterize the role of other RNA modifications in HSC function. From 
healthy stem cells to aberrant leukemia cells, it is becoming clear that epitranscriptional 
regulation is a powerful mechanism for influencing cell fate and a promising target for potential 
therapeutics.  
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Figure 4.1 METTL3 and m6A regulates hematopoietic stem cells (HSCs) both cell-
intrinsically and –extrinsically. 
(a) m6A on Myc mRNA promotes MYC translation and is required for HSC differentiation.
(b) m6A in embryonic Prx1+ mesenchymal stromal cells is required for development of CXCL12-
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APPENDIX A: EXPERIMENTAL METHODS 
 
Mice 
Mx1-cre (Kuhn et al., 1995), Lysm-cre (Clausen et al., 1999), Myc-GFP (Huang et al., 2008), 
and Rosa-loxpMyc (Calado et al., 2012) mice were obtained from the Jackson Laboratory and 
maintained on C57BL/B6 background. Rosa26-creER mice (de Luca et al., 2005) were 
generated and provided by Dr. T. Ludwig at Columbia University. Prx1-cre (Logan et al., 2002) 
and CAG-loxP-stop-loxP-ZsG (Madisen et al., 2010) were obtained from the Jackson 
Laboratory and maintained on C57BL/B6 background. Other mice used in this study included 
Cxcl12DsRed (Ding and Morrison, 2013). Mettl3fl mice were generated by electroporation of a 
targeting vector (obtained from the Knockout Mouse Project Repository, KOMP) into V6.5 
embryonic stem (ES) cells. Correctly targeted ES cell clone, validated by PCR and southern blot 
analysis, was identified and injected into BDF1 blastocysts and chimeric mice were generated. 
Chimeric mice were bred with C57BL/6 mice to obtain germline transmission. The resulting mice 
were crossed with Flpe mice (Rodriguez et al., 2000) to remove the Neo cassette. These mice 
were backcrossed at least 6 times onto C57BL/6 background before analysis. To induce Cre 
expression in Mx1-cre; Mettl3fl/fl or Mx1-cre; Mettl3fl/fl; Rosa-loxPMycfl/fl mice, 6-8wk old animals 
were intraperitoneally injected with 10ug polyinosinic-polycytidylic acid (pIpC, GE or InvivoGen) 
in PBS every other day for 5 injections. Mice were analyzed either 10-14 days, 2-3 months, or 4 
months after the final injection, as indicated in each experiment. To induce Cre expression in 
Rosa26-CreERT2; Mettl3fl/fl mice, recipients were given 1ug tamoxifen in 50uL corn oil by 
gavage every other day for 5 doses. All mice were housed in specific pathogen-free, 
Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC)- 
approved facilities at the Columbia University Medical Center. All protocols were approved by 
the Institute Animal Care and Use Committee of Columbia University. The study is compliant 





Genotyping PCR Primers 
The following primers were used for genotyping:  
Mettl3fl allele: GTTGATGAAATTATCAGTACAATGGTTCTGA; 
GTAAAGAACAACTCTGGTTATCGTCATCG. 




For 5-fluorouracil (5-FU; Sigma-Aldrich) treatment, Mx1-cre; Mettl3fl/fl and littermate control mice 
were treated with pIpC as previously described. 10 days after the last pIpC injection, mice were 
injected intraperitoneally with 150 mg/kg 5-FU weekly until death or experimental conclusion.  
 
Complete Blood Counts 
Peripheral blood was collected by tail vein or cardiac puncture into EDTA-coated capillary tubes. 
Blood samples were analyzed by Genesis (Oxford Science Inc). 
 
Flow cytometry 
Bone marrow cells were isolated by flushing the long bones or by crushing the long bones, 
pelvis, and vertebrae with mortar and pestle in Ca2+ free and Mg2+ free HBSS with 2% heat-
inactivated bovine serum. Splenic cells were obtained by crushing the spleens between two 
glass slides. The splenic and bone marrow cells were passed through a 25G needle several 
times and filtered through 70µm nylon mesh. The following antibodies were used to perform 
HSC staining: lineage markers (anti-CD2 (RM2-5), anti-CD3 (17A2), anti-CD5 (53-7.3), anti-
CD8a (53-6.7), anti-B220 (6B2), anti-Gr-1 (8C5), anti-Ter119(TER-119), anti-Sca-1 (E13-161.7), 
anti-c-kit (2B8), anti-CD48 (HM48-1), anti-CD150 (TC15-12F12.2). Additionally, the following 




(Ding and Morrison, 2013): lineage markers (anti-CD2 (RM2-5), anti-CD3 (17A2), anti-CD5 (53-
7.3), anti-CD8a (53-6.7), anti-B220 (6B2), anti-Gr-1 (8C5), anti-Ter119(TER-119), anti-Sca-1 
(E13-161.7), anti-c-kit (2B8), anti-CD34 (RAM34), anti-FLT3 (A2F10), anti-CD16/32 (93), anti-
IL7Ra (A7R34). 
 
For flow cytometric analysis of bone marrow stromal cells, bone marrow was flushed or crushed 
from the hindlimbs using HBSS with 2% bovine serum. Whole bone marrow was then digested 
with Collagenase IV (200U/ml) and DNase I (200U/ml)	at 37oC for 20 minutes. Samples were 
then stained with antibodies and analyzed by flow cytometry. Anti-CD140a (APA5), anti-CD45 
(30F-11) and anti-TER119 (TER-119) antibodies were used to isolate perivascular stromal cells. 
For intracellular staining, cells were fixed and permeabilized using the eBioscience Transcription 
Factor Staining kit per manufacturer’s instructions. Cells were then stained with antibodies anti-
CXCL12-FITC (R&D, ICF350F) and mouse IgG1k-FITC (MOPC-21) in eBioscience 
permeabilization buffer and analyzed by flow cytometry. 
 
Cell cycle, DNA damage, cell death, reactive oxygen species analysis.  
For BrdU incorporation analysis, mice intraperitoneally injected with 0.1mg/kg BrdU and 
maintained on 0.5mg/ml BrdU water for 5 days before the analysis. The frequency of BrdU+ 
cells was determined by flow cytometry using an APC BrdU Flow Kit (BD Biosciences) per 
manufacturer’s instructions. To measure γH2AX levels, cells were stained for SLAM markers, 
fixed and permeabilized (BD Biosciences BrdU Flow Kit) and stained with anti-γH2AX 
(Biolegend, clone 2F3), followed by flow cytometry. Annexin V staining was performed using 
Annexin V Apoptosis Detection Kit APC (eBioscience) per manufacturer’s instructions. ROS 
levels were measured by DCFDA staining (29-79-dichlorofluorescein diacetate, ThermoFisher 
Scientific). After antibody staining, cells were incubated with 10uM DCFDA for 15 minutes at 





Long-term competitive reconstitution assay 
Adult recipient mice were lethally irradiated by a Cesium 137 Irradiator (JL Shepherd and 
Associates) at 300 rad/min with two doses of 540 rad (total 1080 rad) delivered at least two 
hours apart. Cells were transplanted by retro-orbital venous sinus injection of anesthetized 
mice. Mice were transplanted with either 5 x 105 donor and 5 x 105 competitor bone marrow 
cells or 50 sorted donor HSCs and 3 x 105 competitor bone marrow cells, as indicated. Donor 
mice were either untreated or sacrificed10 days after pIpC treatment, as indicated. For limiting 
dilution assays, mice were transplanted with 3 x 105 competitor bone marrow cells and either 
10,000, 30,000, or 80,000 bone marrow cells as indicated. Recipient mice were temporarily 
maintained on antibiotic water (Baytril 0.17g/L) for 14 days after transplantation. Peripheral 
blood from recipient mice was analyzed by flow cytometry at indicated timepoints for at least 16 
weeks after transplantation to assess the level of donor-derived blood lineages (donor 
chimerism), including myeloid, B, and T cells. For post-transplantation Cre-induction 
experiments, recipients’ peripheral blood was analyzed over at least two time points at least 6-8 
weeks after transplantation to ensure stable engraftment before treatment with pIpC (10ug per 
mouse per dose for 5 doses) or tamoxifen (1ug per mouse per dose for 5 doses). For limiting 
dilution assays, recipient mice were considered reconstituted if they contained donor myeloid, B 
and T cells in their peripheral blood cell above background levels at both 8 weeks and 16 weeks 
post-transplantation. Blood was subjected to ammonium chloride potassium red cell lysis before 
antibody staining. Antibodies including anti-CD45.2 (104), anti-CD45.1 (A20), anti-CD3 (17A2), 
anti-B220 (6B2), anti-Gr1 (8C5), and anti-Mac1 (M1/70) were used to stain cells.   
 
Colony-forming unit assay 
10,000 bone marrow cells, 100,000 spleen cells, 200 LSK cells, single MPP, single HSCs or 




STEMCELL Technologies) and incubated at 37°C. Colonies were counted 9-12 days after 
plating on an Olympus CKX41 microscope (Olympus) and scored as derived from erythroid 
progenitor cells (BFU-E and CFU-E), granulocyte-macrophage progenitor cells (CFU-GM, CFU-
G and CFU-M), megakaryocyte progenitor cells (CFU-MK) and multipotent granulocyte, 
erythroid, macrophage and megakaryocyte progenitor cells (CFU-GEMM). 
 
Viral transduction and colony-forming assay 
Retroviruses were produced by transfecting 293T cells with pMIG-Myc (Addgene plasmid 
#18119) or pMIG vectors along with pCL-Eco and collecting media after 48-72hrs. Virus titers 
were determined by transduction of NIH-3T3 fibroblasts with serial dilutions of viral media. 200 
HSCs were sorted from Mx1-cre; Mettl3fl/fl mice 10 days after pIpC treatment and plated into 
DMEM with 15% heat-inactivated fetal bovine serum, 100ng/ml SCF, 10ng/ml IL-3, 10ng/ml IL-6 
and 50μM b-mercaptoethanol. Cells were transduced with >120 MOI retrovirus particles in the 
presence of 8ug/mL polybrene and spun at 1400g for 1.5hrs at 20°C. Cells were then collected 
and plated in 1.5mL of methylcellulose culture medium and incubated at 37°C for 9-12 days. 
Colonies were collected in bulk and resuspended in Ca2+- and Mg2+-free HBSS with 2% heat-
inactivated bovine serum before staining with antibodies. Cells were then analyzed by flow 
cytometry. 
 
Macrophage Culture and phagocytosis assay 
One million whole bone marrow cells were plated in 12-well plates and cultured at 37°C in 
Dulbecco's Modified Eagle Medium (DMEM; Thermo Fisher) supplemented with 10% Fetal 
Bovine Serum (LifeTech) and 30% L929 supernatant. After 6 days, non-adherent cells were 
removed and macrophages were re-plated in fresh medium. Stimulation and phagocytosis 




For stimulation assays, 1ug/mL lipopolysaccharides (LPS; Sigma) were added to cells for 3 
hours. Stimulated and unstimulated control cells were harvested into Trizol (Invitrogen) and 
RNA was isolated according to manufacturer’s instructions. Samples were reverse transcribed 
and subject to qPCR, as previously described. 
 
For phagocytosis assays, cells were incubated for 1 hours at 37°C or 4oC at a multiplicity of 
infection (MOI) of 1∶50 with Fluoresbrite® carboxylate microspheres (Polyscience), washed in 
PBS with 1% FBS. Non-adherent cells and excess microspheres were removed by washing with 
DMEM before macrophages were collected and analyzed by flow cytometry. 
 
Histopathology and immunostaining  
For histopathology analyses, freshly dissected long bones were fixed in 4% paraformaldehyde 
at 4oC for 24 hours. They were stored in 70% ethanol before being decalcified, paraffin 
embedded, sectioned and stained with hematoxylin and eosin. For immunostaining, long bones 
were fixed in a formalin-based fixative at 4oC for 2 hours. Bones were then embedded in 8% 
(w/v) gelatin in PBS. Samples were snap-frozen with liquid nitrogen and sectioned by cryostat. 
Sections were dried overnight at room temperature and stored at -80oC. Sections were 
rehydrated in PBS for 5 minutes before immunostaining. Slides were mounted with HardSet 




Cells were sorted directly into Trizol. Total RNA was extracted according to manufacturer’s 
instructions. Total RNA was subjected to reverse transcription using SuperScript III (Invitrogen). 




actin was used to normalize the RNA content of samples. Primer sequences: b-
actin:  GCTCTTTTCCAGCCTTCCTT; CTTCTGCATCCTGTCAGCAA. Mettl3: 
AAGGAGCCGGCTAAGAAGTC; TCACTGGCTTTCATGCACTC. Myc: 
TCTCCCCAAGGGAAGACGAT; TTGCTCTTCTTCAGAGTCGCT Tnfa: 
GGAACTGGCAGAAGAGGCACTC; GCAGGAATGAGAAGAGGCTGAGAC. Il6: 




poly(A)+RNA was isolated from whole bone marrow cells or sorted HSCs using Dynabeads 
Oligo-(dT)25 magnetic beads (ThermoFisher Scientific) according to manufacturer’s 
instructions. 1.25 μg of anti-m6A antibody (Synaptic Systems) was pre-bound to Protein A/G 
magnetic beads (Millipore) in IP buffer (20-mM Tris pH 7.5, 140-mM NaCl, 1% NP-40, 2-mM 
EDTA) for 1 h. Sample RNA was incubated with antibody-bound Protein A/G beads for 2 hours 
at 4 ºC. Samples were washed twice in low-salt-wash buffer (10-mM Tris pH 7.5, 5 mM EDTA), 
twice with high-salt-wash buffer (20-mM Tris pH 7.5, 1-M NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS, 1-mM EDTA) and twice with RIPA buffer (20-mM Tris pH 7.5, 150-
mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1-mM EDTA). All wash solutions 
for each sample were collected as the “unbound” fraction. RNA was eluted from the beads by 
incubating with 50μl 20mM N6-methyladenosine 5-monophosphate sodium salt (Sigma- Aldrich) 
for 1hr at 4 ºC. Following ethanol precipitation, input, unbound, and m6A-bound fraction RNA 
was reverse-transcribed using Superscript III (Invitrogen) with random hexamers. Enrichment of 
m6A-containing transcripts was determined by quantitative PCR relative to Rplp0 expression. 






RNA-seq and meRIP-seq 
For RNA-seq, libraries were prepared according to the Smart-seq2 protocol as described (Picelli 
et al., 2014) from 150 sorted HSCs from Mx-1cre; Mettl3fl/fl or control mice 10 days after pIpC 
treatment. Three control and four Mx-1cre; Mettl3fl/fl biological replicate samples were 
sequenced by Illumina HiSeq 2500 with paired-end 100-bp read length.  
 
For meRIP-seq, poly(A)+RNA was isolated from 3,000 sorted HSCs from C57BL/6J mice or Mx-
1cre; Mettl3fl/fl mice 10 days after pIpC injection using Dynabeads Oligo-(dT)25 magnetic beads 
(ThermoFisher Scientific) according to manufacturer’s instructions. 1.25 μg of anti-m6A antibody 
(Synaptic Systems) or rabbit IgG (Jackson ImmunoResearch) was pre-bound to Protein A/G 
magnetic beads (Millipore) in IP buffer (20-mM Tris pH 7.5, 140-mM NaCl, 1% NP-40, 2-mM 
EDTA) for 1 h. Sample RNA was incubated with antibody-bound Protein A/G beads for 2 hours 
at 4 ºC. Samples were washed twice in low-salt-wash buffer (10-mM Tris pH 7.5, 5 mM EDTA), 
twice with high-salt-wash buffer (20-mM Tris pH 7.5, 1-M NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS, 1-mM EDTA) and twice with RIPA buffer (20-mM Tris pH 7.5, 150-
mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1-mM EDTA). All wash solutions 
for each sample were collected as the “unbound” fraction. RNA was eluted from the beads by 
incubating with 50μl 20mM N6-methyladenosine 5-monophosphate sodium salt (Sigma) for 1hr 
at 4 ºC. Following ethanol precipitation, RNA from input, m6A-antibody unbound, and m6A-
antibody eluted, and IgG eluted fractions was reverse transcribed, amplified, tagmented and 
index according to the Smart-seq2 protocol (Picelli et al., 2014). Three biological replicate 
samples were sequenced by Illumina HiSeq 2500 or NextSeq 500 with paired-end 100-bp or 
150-bp read length. 
 
Analysis of RNA-seq and meRIP-seq data was performed using the Quantas pipeline 




modifications.  In brief, raw reads were mapped to the mouse genome and an exon-junction 
database using OLego (Wu et al., 2013). Due to the low input during library preparation, 
potential PCR duplicates were removed using Picard (http://broadinstitute.github.io/picard). 
Exonic and junction reads were then counted to estimate transcript abundance (read per 
kilobase per million reads, or RPKM) and perform differential expression analysis using edgeR 
(Robinson et al., 2010).  
 
Cumulative distribution analysis of RNA-seq log2 fold changes in expression between Mettl3-
depleted and control HSCs was performed in R using the ecdf function. Groups were defined as 
m6A (meRIP-seq FDR<0.05, FC>2) or non-m6A (the rest of the genes), excluding genes with 
RNA-seq RPKM <1 for both Mettl3-depleted and control HSCs. Significance of difference 
between the cumulative distribution curves was determined using Kolmogorov–Smirnov test. 
 
Statistics and Reproducibility 
All experiments were repeated on biological replicates independently with similar results. The 
exact sample sizes for each experiment were indicated in figure legends. All statistics 
comparing two groups used two-sided Student t-test. The Kaplan-Meier estimation and two-
sided log-rank test were used to compare survival difference between mouse groups. Statistical 
analyses were performed with Microsoft Excel or GraphPad Prism7.  
 
Data Availability 
Sequencing data that support the findings of this study have been deposited in the Gene 
Expression Omnibus (GEO) under accession code GSE123527. All other data supporting the 
findings of this study are available from the corresponding authors on reasonable request. 
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APPENDIX B: m6A TARGETS 
995 transcripts found to be methylated in wild-type HSCs (log2(FC)>1 and FDR<0.05) with 
significantly decreased m6A enrichment in Mettl3Δ/Δ compared to wild-type HSCs (p<0.05). 
Gene names are listed along with their m6A enrichment in wild-type HSCs (expressed as 
log2(FC)). 






































































Gene Name log2 (FC) 
Ifnar1 6.996 
Nup50 5.464 
Morc2a 7.434 
Atxn7l3b 4.761 
2700089E24Rik 4.456 
Slc44a2 3.236 
Adipor2 3.107 
D230037D09Rik 7.287 
Tspyl1 5.197 
Il21r 3.911 
Paqr7 4.147 
AI467606 3.861 
Yars 3.370 
Slfn2 4.871 
A830007P12Rik 4.815 
Cdc42ep3 4.454 
Sephs2 5.519 
Icam1 4.711 
Crkl 9.388 
Zfp956 7.280 
Fen1 3.569 
Chtf8 3.407 
Lpar6 6.890 
Thap7 3.756 
Sertad1 6.830 
Sfxn1 3.035 
Mtap 3.553 
Stim2 6.989 
Keap1 6.084 
Mgat1 5.978 
Znrf1 4.184 
Gna15 5.849 
Ifi47 3.649 
H2-Q6 3.968 
		
	
103 
Mycn 3.783 
Rrp36 4.636 
Gemin7 3.972 
Rcsd1 4.078 
D19Ertd386e 7.943 
6230427J02Rik 3.454 
Zfp202 8.842 
Fam105b 5.006 
2510039O18Rik 4.638 
Usp10 5.220 
Cog8 3.993 
Sdpr 4.666 
Cops8 2.983 
Nfe2 2.769 
Neurl3 3.923 
G3bp2 3.040 
Fam57a 4.861 
1110054O05Rik 4.215 
Dgcr14 3.163 
Adprhl2 3.443 
Galnt2 3.725 
Snord88a 3.924 
Csrp2bp 6.244 
Afg3l2 3.538 
Rnpepl1 4.163 
B9d2 3.493 
Bag4 7.446 
Slc22a3 3.651 
Slx4 10.521 
Sec24b 5.734 
Klf10 3.688 
Ndst2 4.019 
Vamp5 2.895 
Selplg 2.822 
Pdia4 2.903 
St6galnac4 6.021 
Cdca4 3.742 
Zc3h11a 5.131 
Txnl4a 2.488 
Rhoh 4.071 
Fli1 3.327 
St3gal2 7.514 
Smad2 3.172 
Krba1 8.752 
Nxt1 3.523 
Eif1a 3.401 
Imp3 3.040 
Antxr2 8.079 
Fem1c 8.080 
Mettl13 6.722 
Zfp869 6.248 
Emilin2 8.784 
Erp29 2.838 
5930416I19Rik 3.986 
Ip6k1 3.697 
Arhgap29 8.791 
Gm962 12.947 
Hmg20a 3.767 
Ninj1 2.646 
Klf13 4.638 
Peo1 3.255 
Fbxo5 4.732 
Nck1 4.989 
Ifngr1 2.882 
Rrp15 3.239 
Pglyrp2 2.958 
Wdr73 3.241 
Pde4b 5.872 
Cmpk2 4.844 
Cep68 4.317 
Nif3l1 3.034 
H1f0 2.725 
Slc15a4 7.258 
Toe1 4.918 
Vps4a 2.901 
Igtp 3.258 
Twistnb 3.189 
Setd2 6.461 
Rbmxl1 3.551 
Ppp2r1b 2.807 
Slc35a4 2.619 
Plk4 6.316 
Irgm1 4.584 
Polr2m 2.513 
Ccm2 2.545 
Trappc5 2.827 
Rpp38 7.589 
Nkx2-3 5.315 
Gimap1 3.382 
Fbxl4 6.989 
Psen1 3.609 
Rap2b 6.148 
Naa40 3.181 
Rnf19a 7.985 
C1rl 4.594 
Tbc1d10c 2.270 
Elf2 4.612 
Cd27 2.344 
Junb 3.434 
Isg20l2 3.468 
F2rl3 3.782 
Agpat6 4.298 
Kti12 3.143 
Zbtb24 6.843 
Tfam 2.951 
Ints5 6.169 
Pcyox1 4.985 
Prkab1 3.534 
2010321M09Rik 2.722 
Ccdc69 3.806 
Zfp777 8.356 
Lrrc14 3.872 
Ppp2r2a 2.823 
Ldlrap1 2.890 
B4galt4 5.670 
Parg 6.723 
Poli 5.748 
Tlr2 8.157 
2810408M09Rik 6.651 
Cant1 3.517 
Gpr125 9.285 
Zfp422 3.036 
Flcn 3.208 
Qrich1 3.641 
Srxn1 7.836 
Umps 2.844 
Krcc1 3.432 
Mesdc1 6.144 
Gimap5 2.714 
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Arid1a 5.736 
Akap1 7.605 
Ier2 2.920 
Ppm1g 2.131 
Fbxo46 8.397 
Ccdc66 7.129 
Slfn9 7.258 
Slc16a9 7.901 
Mppe1 2.751 
Zbtb2 8.378 
Zmym1 8.123 
Socs6 8.525 
Rb1cc1 6.781 
Tmem177 5.814 
Fkrp 8.249 
1110057K04Rik 3.625 
Cbx2 9.534 
Slc1a5 2.137 
Tesk2 5.746 
Xylt2 9.094 
A230050P20Rik 2.747 
Mak16 2.678 
Mgat2 3.301 
Pdf 2.915 
Usf1 4.443 
Crk 5.136 
Rabif 4.095 
Ctso 3.934 
B3gnt2 5.603 
Dhx33 8.925 
Zfp324 9.776 
Zfp46 9.908 
Pias1 3.686 
Ccdc32 4.836 
Rcl1 2.425 
Gata2 2.289 
P2ry2 8.004 
3110056O03Rik 2.766 
Elovl1 2.240 
Zfp386 4.493 
Csk 2.188 
E130304F04Rik 12.460 
Ado 3.867 
Rilpl1 5.657 
Atg13 4.048 
Fam110a 4.773 
Slco4a1 4.061 
Zcchc17 2.615 
Tor1aip2 4.004 
1110034A24Rik 3.296 
Zfp58 7.956 
Hpse 8.933 
9030418K01Rik 7.517 
Rrs1 4.541 
Mtpap 3.743 
Brip1 6.624 
Ywhah 2.122 
Rragc 4.665 
Cebpz 2.755 
Ttpal 5.077 
Pank2 2.751 
Sp3 3.006 
Tbxa2r 3.489 
Fbxo34 8.222 
Ppp4r1 4.871 
Men1 2.729 
Dusp6 4.123 
Rhog 2.526 
Tnfsf14 7.447 
Atp5sl 2.800 
1700040I03Rik 3.801 
Gspt2 8.720 
Ehd4 3.018 
Pnrc1 2.536 
Zfand5 2.060 
Trmt5 8.728 
Chpf2 4.174 
Arsa 2.868 
Lphn2 7.756 
Gmeb2 7.431 
Wtap 2.670 
Tmem246 3.969 
Pias4 3.463 
Limd1 5.427 
Rtp4 4.967 
Dedd2 6.132 
Klhl9 4.064 
Adpgk 3.507 
Mrps7 2.579 
Tmem186 5.098 
Zfp961 7.042 
Golph3l 3.535 
Prosc 3.777 
Zfp955b 9.417 
Pard6b 9.676 
Gm4951 9.391 
Slc43a3 2.234 
Bag5 5.225 
AI480653 5.021 
Mettl6 4.790 
Gmppb 3.219 
Fam69b 2.477 
Rab35 3.654 
Sdccag3 3.282 
Tagap 7.442 
Tmem140 3.105 
BC003965 4.277 
Abhd15 4.892 
Mif4gd 2.763 
Adnp2 7.231 
Ccdc21 3.604 
Dem1 5.402 
Sema4b 4.234 
Ccdc86 2.857 
Mier3 6.754 
Ctdp1 4.894 
Rit1 2.891 
Tradd 3.696 
4930453N24Rik 4.766 
Fut10 5.780 
Rnf26 4.479 
Sap30bp 3.582 
Gab2 9.803 
Orc2 2.480 
Fam179b 9.214 
Gcnt1 6.720 
1110002N22Rik 5.612 
Ammecr1l 4.436 
Lcmt2 6.260 
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4930444A02Rik 6.059 
Fam134b 3.906 
Palb2 7.282 
Pms2 3.498 
Ftsj2 9.546 
Pdcl 4.008 
Dynll1 2.274 
Inpp1 3.576 
Orai3 2.656 
2410016O06Rik 3.790 
Rnf145 3.687 
4831426I19Rik 9.104 
Tmem11 3.675 
Zfp870 8.578 
Rlf 7.447 
Ptpn22 3.237 
Asb8 5.191 
Sesn1 2.201 
Cd79b 3.180 
Yipf5 3.529 
Rnf8 2.735 
Zfp472 6.959 
S1pr4 2.582 
Chmp1b 5.039 
Tk2 2.747 
Slc19a1 2.292 
Cdv3 3.146 
Nrbf2 8.052 
Gp5 3.594 
BC147527 11.979 
Tut1 4.116 
Tysnd1 2.950 
Rora 9.693 
Taf3 6.972 
Mcl1 3.118 
Clp1 4.788 
Zdhhc7 3.409 
Nipbl 5.140 
Sac3d1 3.642 
Fignl1 4.598 
Tmem115 4.477 
Rg9mtd1 4.059 
Nol12 2.620 
Fgd5 8.106 
Nlgn2 6.499 
Dcun1d1 3.333 
Tmem104 5.868 
2310003H01Rik 3.736 
Mcm9 3.116 
1810048J11Rik 5.519 
Gm16517 3.365 
Wdr55 2.348 
Mlycd 3.313 
1700017B05Rik 5.855 
Tssc4 2.293 
Mrpl41 3.171 
Wdr85 2.862 
Aldh1b1 9.020 
Smcr7l 4.448 
B3gnt5 8.286 
Rinl 3.946 
Inpp5e 2.460 
Hs3st1 9.343 
Sppl3 3.265 
Prpf4 3.232 
Tnrc6c 6.387 
Zfp64 3.823 
Tmem41a 2.375 
Ptgs1 2.082 
Dsn1 3.554 
Ptrh2 3.489 
Zfp771 2.703 
Pter 6.355 
Lhfpl2 7.661 
Plekhg5 9.514 
Ubap1 2.975 
H2afx 2.067 
Fam58b 4.798 
Dos 5.035 
Zmym2 4.595 
Fam136a 3.087 
Mettl11a 2.476 
Ubl3 3.366 
Gadd45g 4.176 
Gtdc2 4.972 
Extl2 5.173 
Tspyl3 4.826 
Mtrf1l 6.277 
Mrpl43 2.285 
BC006779 9.189 
Zfp282 6.024 
Thsd1 7.577 
Gnaz 8.894 
2310003C23Rik 2.945 
0610011L14Rik 3.218 
Aqp9 3.596 
Rft1 2.710 
Tab2 7.474 
Trex1 3.473 
A730011L01Rik 3.708 
Mrpl12 1.785 
Cables1 5.258 
Cdc25a 3.433 
Spata2 5.788 
Arl4a 4.525 
Panx1 3.511 
Adora2a 4.062 
6330503K22Rik 6.076 
Dnajb9 3.724 
Adam17 2.309 
Hps6 8.386 
Zfp809 5.258 
Litaf 2.477 
Gcc2 5.699 
Gpr157 12.104 
2400003C14Rik 2.040 
Tmem185b 5.434 
Brms1 1.940 
Fam174b 3.160 
Bet1l 3.988 
Plekhg2 8.018 
Kctd20 2.444 
Dctn5 1.923 
Klf9 6.548 
Tifa 3.810 
Gpn2 3.004 
Gpr171 4.000 
Fzd7 8.712 
Snx20 5.216 
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Abcb9 8.340 
9130023H24Rik 6.639 
Nudt1 2.589 
Slc39a7 1.771 
Socs2 3.885 
Gsg2 7.312 
Zscan22 6.635 
Fut7 4.847 
Btbd7 8.003 
Egln2 1.996 
Endod1 8.377 
Kcnn4 1.677 
Gatc 2.963 
Foxo1 9.095 
Il15ra 3.480 
Pla2g15 4.083 
D4Wsu53e 1.977 
Slc25a46 3.236 
Zdhhc3 1.968 
Klhl25 10.102 
3110062M04Rik 2.506 
Tnfaip8l1 9.278 
Metrnl 8.945 
E330016A19Rik 6.903 
AA987161 7.989 
Zfp773 8.011 
4632434I11Rik 7.538 
Ccdc85b 3.568 
Fam116a 2.635 
Gins3 6.704 
Ywhag 2.426 
Ttl 7.413 
Zkscan5 5.891 
Flywch1 2.729 
Yeats4 1.957 
Mfap3 4.576 
Tusc2 2.782 
P2ry14 7.872 
Ndnl2 5.390 
Sec22a 3.566 
Sash1 9.919 
Cdk9 3.577 
Gusb 1.742 
Fiz1 2.680 
Ctdspl 7.545 
Mrps26 1.960 
Gm12250 5.473 
Pofut2 2.174 
Zfp11 11.476 
A630001G21Rik 4.709 
Mmaa 3.284 
Slc35c2 1.792 
2310008H09Rik 3.072 
Mrps2 2.876 
Cpd 9.023 
Cnpy3 2.222 
Txndc11 2.528 
2310011J03Rik 2.257 
Rab38 1.740 
Shoc2 3.196 
4931414P19Rik 8.092 
4833420G17Rik 2.258 
Nat6 2.786 
Rara 7.101 
Psmd5 1.768 
Rbak 9.402 
Tmem121 8.880 
Elk3 3.047 
Dars2 2.449 
Rab31 2.413 
Elmod3 3.059 
Klhl26 5.161 
Slc35b3 2.648 
Eme2 2.091 
Mdm2 3.370 
Pik3ca 7.266 
Lsm10 3.370 
Ffar2 6.203 
4933403G14Rik 11.325 
Cbll1 3.829 
B3gntl1 3.656 
Lass4 2.040 
Mrps27 2.402 
Sdhaf2 3.765 
2810432D09Rik 3.368 
Zfp639 4.508 
Bivm 4.255 
1700123O20Rik 2.529 
Scamp4 1.977 
Myct1 2.021 
Six5 6.121 
Gata3 4.026 
Cops2 2.152 
Zfp191 6.149 
Cinp 2.761 
Mcart1 2.696 
Cpt2 3.988 
Pi4kb 4.848 
Glrp1 8.991 
Icam2 1.905 
Slc16a6 4.434 
Zfp87 2.959 
Itpk1 2.488 
Hyal2 3.869 
Dicer1 5.446 
Zfp280b 7.779 
Slc43a2 4.421 
Utp3 2.842 
Tsen54 2.271 
Hmox2 1.702 
2900026A02Rik 7.891 
Slc35e4 4.395 
Zbtb45 3.828 
Asnsd1 1.882 
Zkscan6 3.433 
Sphk2 2.763 
Abt1 4.008 
Dph2 2.891 
Slc36a4 7.846 
2210020M01Rik 2.581 
2410002F23Rik 3.715 
Snrk 5.122 
Mad2l1bp 4.119 
Jmjd4 5.740 
Chmp1a 1.711 
Chd9 4.563 
Ehbp1 7.723 
Zfp142 7.397 
Cln5 3.256 
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Ccdc71 4.435 
Rhob 3.940 
Dclre1b 3.772 
Stx5a 1.964 
Zfp456 7.932 
BC055004 5.444 
Pck2 1.789 
Fem1a 6.528 
Arglu1 3.054 
Ccdc88c 8.328 
Neu1 3.555 
Gpn1 1.994 
Susd3 2.556 
Lig3 3.701 
Ddit3 2.728 
Fam55c 5.486 
Dph5 2.386 
Jtb 1.978 
Tet2 6.190 
Med18 6.675 
Rffl 2.723 
2010015L04Rik 9.330 
S1pr2 4.800 
1810058I24Rik 1.829 
Map1lc3b 1.637 
Rdh11 2.538 
Zfp784 7.770 
2810008M24Rik 2.807 
Mn1 8.510 
Irf2bp2 5.191 
Kpna6 4.394 
Tmub2 1.927 
Mdfic 6.910 
Snip1 3.613 
Batf 2.266 
2610035D17Rik 3.956 
Cd3eap 2.906 
Eri2 6.766 
Zfp161 5.995 
Gng11 1.845 
Dexi 3.958 
2700078E11Rik 4.343 
Zfp810 9.142 
Orai1 2.409 
Gdf3 2.757 
Spsb4 8.293 
Mudeng 3.561 
Slc16a13 4.755 
Xbp1 1.611 
Zbtb25 5.286 
Slc37a3 7.865 
Acpl2 2.697 
Zmat1 6.018 
Tuba8 1.788 
Fuca2 2.326 
Mfhas1 8.489 
Snapc2 2.530 
AI837181 5.426 
Pi4k2a 4.452 
Haus6 5.936 
Phf23 3.661 
Tgif1 3.751 
Fancm 9.137 
Fam109a 5.402 
Cxxc5 2.497 
1810055G02Rik 7.929 
Zfp780b 7.646 
Sco2 2.141 
Tnfsf4 7.999 
Rnf122 3.730 
Zscan29 6.975 
Arfgap1 4.420 
Zfp85-rs1 7.660 
Spsb2 3.851 
Ube2d1 2.871 
Ptp4a3 1.468 
Ythdf3 5.322 
D16Ertd472e 2.971 
Rrp7a 1.771 
Rspry1 3.164 
Wdr81 8.757 
Lipt1 6.751 
Dscr3 2.562 
Slc7a6 1.926 
Lias 2.169 
Cdadc1 2.751 
Znrd1as 9.149 
Terf2ip 4.317 
Vps37b 3.570 
Ikbip 5.472 
Rps19bp1 2.560 
Hyls1 7.758 
Trim13 5.465 
Thtpa 2.630 
Ccdc59 2.832 
Gpr107 3.541 
Rnf185 4.866 
Nat2 7.574 
Sigmar1 1.895 
Acot11 5.327 
Ppp1r15b 3.524 
Homez 5.375 
9430023L20Rik 2.207 
Dolk 4.915 
Rad51ap1 2.621 
H2-Q7 1.707 
Htr2a 8.186 
Fbxo22 1.874 
Psmd7 1.509 
Lrrc8a 5.138 
Alg11 4.797 
St3gal1 3.270 
Ndufaf1 2.504 
Zswim1 5.562 
Thap11 2.801 
2310022A10Rik 2.622 
Bcl11a 1.699 
Pcyox1l 3.722 
Msl3l2 4.649 
2010111I01Rik 2.671 
Cwc25 4.613 
Kbtbd2 4.711 
Spry1 7.928 
Slc30a5 1.606 
Gimap9 3.404 
Fdxr 2.060 
Spred1 3.840 
8030462N17Rik 10.417 
Dedd 2.605 
		
	
108 
Btbd8 10.410 
Paqr8 7.188 
Kctd1 2.745 
Il17re 3.060 
Tmem17 7.521 
Tmem44 6.262 
Arl11 8.257 
Pop7 2.582 
Zfp260 3.201 
Ppp2r5e 2.834 
Triap1 3.343 
Ngrn 2.463 
Ttll4 5.735 
Zkscan14 3.737 
Slc10a3 2.089 
Ephb4 9.667 
Zfp189 8.810 
Tor1a 1.733 
Rpusd4 2.484 
1810008A18Rik 2.132 
Irf3 1.568 
Spsb3 1.936 
Ptprcap 1.375 
Angptl4 2.932 
Maml3 8.727 
2700007P21Rik 3.764 
Zfp770 9.987 
2010002N04Rik 3.364 
Pigm 4.448 
0610007P22Rik 2.300 
LOC330599 8.995 
Zfp958 4.266 
Zfp710 4.066 
Pcbp1 1.346 
Cdc26 1.710 
Adck2 1.905 
Zbed6 8.074 
Commd5 4.418 
Cd276 9.023 
B4galnt1 1.814 
Mterfd2 2.546 
Mrgpre 7.924 
Usp44 8.360 
Glb1 1.534 
Bnip1 2.502 
Txndc15 1.847 
Ccdc127 3.527 
Zfp429 7.000 
Ercc4 3.791 
Gm20604 3.547 
2610002I17Rik 2.688 
D630039A03Rik 4.451 
Armc10 1.950 
Trappc3 1.707 
Rab43 3.070 
3230401D17Rik 3.641 
Grpel2 4.032 
Slc25a11 1.357 
Leprotl1 1.587 
Med7 2.423 
Rpp14 1.765 
Nupl2 4.337 
Patz1 3.718 
Naip5 3.755 
Zfp609 7.218 
Nudt7 2.418 
Fbxo28 6.315 
Tmem173 1.742 
Fitm2 7.227 
Traf1 4.318 
Xkr5 4.567 
Zfp646 6.841 
Eepd1 5.997 
Sumo1 1.758 
Ubiad1 4.097 
Kbtbd4 2.390 
Grin2d 10.517 
Gemin8 4.184 
Map3k14 7.839 
Mrpl19 1.694 
Fadd 3.771 
Map3k8 6.389 
Tef 3.684 
Gpr132 3.745 
Mapk7 4.262 
Fam110b 5.489 
Pde4c 11.488 
Rnf25 2.070 
Zfp677 8.378 
1810063B07Rik 2.691 
AI462493 1.983 
Rint1 3.021 
Nup62-il4i1 6.578 
Dnajc14 1.543 
1810026J23Rik 1.949 
Havcr2 8.854 
Rnf139 2.729 
Mul1 3.394 
5530601H04Rik 2.247 
Zfp184 10.775 
Armcx6 3.958 
2310014F07Rik 9.461 
Glyctk 8.266 
Kctd21 10.824 
Zfp951 5.649 
Cnnm2 9.072 
Taf11 2.170 
Tmub1 2.652 
Dyrk3 4.287 
Alg9 1.723 
H2-Q9 1.931 
Sertad3 4.373 
Dnajc30 3.592 
Pars2 5.284 
Zc3h6 5.215 
Mrpl50 2.647 
Fam118a 4.259 
Fam108b 3.137 
Cstf1 2.297 
Agpat2 1.627 
2010002M12Rik 7.088 
Nob1 1.570 
Cox19 2.408 
Fam69a 1.961 
Slc10a7 3.164 
Gp9 1.637 
2810422O20Rik 4.973 
Gmpr 1.499 
Ctla2b 1.814 
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Cd200r1 3.020 
Bspry 10.797 
Tmem168 5.302 
Tm2d2 1.488 
Tk1 1.588 
Mbd3 1.399 
6430527G18Rik 6.261 
Notch4 7.688 
Tigd2 4.397 
Kctd14 3.336 
Asb6 2.572 
Zswim6 8.246 
Coasy 1.641 
BC024479 6.493 
Ankrd10 1.354 
2610002D18Rik 5.250 
Clip2 7.730 
Utp15 2.536 
B3galt6 3.069 
Zfp61 4.810 
Mob2 1.857 
Abtb1 2.182 
Sh2d4a 8.406 
C230052I12Rik 4.604 
Sf3b5 1.506 
Ptcd2 1.399 
Gabpb2 3.293 
Epb4.1l1 11.328 
Harbi1 4.996 
Gm9776 7.632 
Slc25a29 8.544 
Msrb2 1.517 
Rp9 1.348 
Pelo 4.324 
Fam192a 1.684 
AW209491 4.980 
Tor2a 1.591 
Herpud2 2.139 
Loh12cr1 4.056 
Ptger4 5.597 
Sephs1 1.946 
Tardbp 1.379 
Cdk13 5.465 
5830416P10Rik 8.149 
Rab19 11.171 
BC017158 1.776 
Amigo3 10.219 
Mir1901 7.645 
Lrfn4 6.796 
Rnf113a2 3.027 
Dnase2a 2.350 
Gm5512 3.000 
Ggn 9.263 
Cno 3.875 
4930547N16Rik 6.178 
Fut4 7.338 
2610029G23Rik 1.545 
Dbr1 3.127 
Fam173b 3.442 
Caml 2.652 
Cxx1c 2.520 
Zfp874b 5.822 
Ppapdc3 4.886 
Hsd3b7 1.250 
Il1r1 8.030 
D17H6S53E 5.626 
Nsd1 2.565 
Ddx59 2.967 
Zfp707 4.705 
Narfl 2.082 
Tob1 4.890 
D330012F22Rik 4.782 
Ydjc 1.750 
Zfp865 4.078 
Btg1 2.940 
Tgif2 2.912 
Ebag9 2.470 
 
 
 
